BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil vs preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68-74. [PMID: 21879261 DOI: 10.1245/s10434-011-2049-9] [Cited by in Crossref: 647] [Cited by in F6Publishing: 597] [Article Influence: 58.8] [Reference Citation Analysis]
Number Citing Articles
1 van den Ende T, Smyth E, Hulshof MC, van Laarhoven HW. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. Best Practice & Research Clinical Gastroenterology 2018;36-37:45-52. [DOI: 10.1016/j.bpg.2018.11.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Miura S, Nakamura T, Hasegawa T, Miura Y, Takiguchi G, Urakawa N, Hasegawa H, Yamamoto M, Kanaji S, Matsuda Y, Yamashita K, Matsuda T, Oshikiri T, Suzuki S, Akashi M, Kakeji Y. Tooth Loss Predicts Long-Term Prognosis of Esophageal Cancer After Esophagectomy. Ann Surg Oncol 2020;27:683-90. [PMID: 31605330 DOI: 10.1245/s10434-019-07903-w] [Reference Citation Analysis]
3 Okamura A, Watanabe M, Kozuki R, Toihata T, Yuda M, Imamura Y, Mine S. Supraclavicular and celiac metastases in squamous cell carcinoma of the middle thoracic esophagus. Langenbecks Arch Surg 2018;403:977-84. [PMID: 30361828 DOI: 10.1007/s00423-018-1722-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Yamashita K, Miyata H, Makino T, Masuike Y, Furukawa H, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Morii E, Mori M, Doki Y. High Expression of the Mitophagy-Related Protein Pink1 is Associated with a Poor Response to Chemotherapy and a Poor Prognosis for Patients Treated with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2017;24:4025-32. [PMID: 29022200 DOI: 10.1245/s10434-017-6096-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
5 Akiyama Y, Iwaya T, Endo F, Chiba T, Takahara T, Otsuka K, Nitta H, Koeda K, Mizuno M, Kimura Y, Sasaki A. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma. Surg Endosc 2018;32:391-9. [PMID: 28664431 DOI: 10.1007/s00464-017-5688-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
6 Okunaka M, Kotani D, Demachi K, Fujiwara H, Sakashita S, Yoshino T, Fujita T, Kojima T. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. Esophagus 2021. [PMID: 34611830 DOI: 10.1007/s10388-021-00885-3] [Reference Citation Analysis]
7 Ishibashi Y, Tsujimoto H, Kouzu K, Itazaki Y, Tsuchiya S, Fujishima S, Yaguchi Y, Sugasawa H, Nomura S, Ito N, Harada M, Nagata H, Shinto E, Kishi Y, Ueno H. Impact of Antiplatelet and Anticoagulant Therapies on Platelet-related Prognostic Markers in Patients With Esophageal Cancer. In Vivo 2020;34:1941-9. [PMID: 32606166 DOI: 10.21873/invivo.11991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Shiozaki A, Kudou M, Fujiwara H, Konishi H, Shimizu H, Arita T, Kosuga T, Yamamoto Y, Morimura R, Ikoma H, Kuriu Y, Kubota T, Okamoto K, Otsuji E. Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC). Medicine (Baltimore) 2020;99:e23633. [PMID: 33327342 DOI: 10.1097/MD.0000000000023633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yamashita H, Omori M, Takenaka R, Okuma K, Kobayashi R, Ohtomo K, Nakagawa K. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study. Radiother Oncol 2014;113:182-7. [PMID: 25466372 DOI: 10.1016/j.radonc.2014.11.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ohi M, Toiyama Y, Yasuda H, Ichikawa T, Imaoka H, Okugawa Y, Fujikawa H, Okita Y, Yokoe T, Hiro J, Kusunoki M. Preoperative computed tomography predicts the risk of recurrent laryngeal nerve paralysis in patients with esophageal cancer undergoing thoracoscopic esophagectomy in the prone position. Esophagus 2021;18:228-38. [PMID: 32743739 DOI: 10.1007/s10388-020-00767-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Brescia AA, Broderick SR, Crabtree TD, Puri V, Musick JF, Bell JM, Kreisel D, Krupnick AS, Patterson GA, Meyers BF. Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer. Ann Thorac Surg 2016;101:200-8; discussion 208-10. [PMID: 26507424 DOI: 10.1016/j.athoracsur.2015.09.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
12 Kataoka K, Takeuchi H, Mizusawa J, Igaki H, Ozawa S, Abe T, Nakamura K, Kato K, Ando N, Kitagawa Y. Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer: Exploratory Analysis of JCOG9907.Ann Surg. 2017;265:1152-1157. [PMID: 27280509 DOI: 10.1097/SLA.0000000000001828] [Cited by in Crossref: 78] [Cited by in F6Publishing: 41] [Article Influence: 15.6] [Reference Citation Analysis]
13 Kosuga T, Shiozaki A, Fujiwara H, Ichikawa D, Okamoto K, Komatsu S, Otsuji E. Treatment outcome and prognosis of patients with lymph node recurrence of thoracic esophageal squamous cell carcinoma after curative resection. World J Surg 2011;35:798-804. [PMID: 21312037 DOI: 10.1007/s00268-011-0978-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
14 Kawamoto T, Shikama N, Mine S, Tsurumaru M, Sasai K. Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients. Esophagus 2020;17:425-32. [PMID: 32170545 DOI: 10.1007/s10388-020-00731-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Zhao Y, Han L, Zhang W, Shan L, Wang Y, Song P, Peng C, Zhao X. Preoperative chemotherapy compared with postoperative adjuvant chemotherapy for squamous cell carcinoma of the thoracic oesophagus with the detection of circulating tumour cells randomized controlled trial. Int J Surg 2020;73:1-8. [PMID: 31756547 DOI: 10.1016/j.ijsu.2019.11.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Mikuni H, Yamamoto S, Kato K. Nivolumab for the treatment of esophageal cancer. Expert Opin Biol Ther 2021;21:697-703. [PMID: 33736560 DOI: 10.1080/14712598.2021.1904887] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Otowa Y, Nakamura T, Yamamoto M, Kanaji S, Matsuda Y, Matsuda T, Oshikiri T, Sumi Y, Suzuki S, Kakeji Y. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer. Dis Esophagus 2017;30:1-5. [PMID: 28881893 DOI: 10.1093/dote/dox107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
18 Iwabu J, Yamashita S, Takeshima H, Kishino T, Takahashi T, Oda I, Koyanagi K, Igaki H, Tachimori Y, Daiko H, Nakazato H, Nishiyama K, Lee YC, Hanazaki K, Ushijima T. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Sci Rep 2019;9:13347. [PMID: 31527639 DOI: 10.1038/s41598-019-50005-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Miura S, Nakamura T, Miura Y, Takiguchi G, Takase N, Hasegawa H, Yamamoto M, Kanaji S, Matsuda Y, Yamashita K, Matsuda T, Oshikiri T, Suzuki S, Kakeji Y. Long-Term Outcomes of Thoracoscopic Esophagectomy in the Prone versus Lateral Position: A Propensity Score-Matched Analysis. Ann Surg Oncol 2019;26:3736-44. [DOI: 10.1245/s10434-019-07619-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kaida H, Kitajima K, Nakajo M, Ishibashi M, Matsunaga T, Minamimoto R, Hirata K, Nakatani K, Hung A, Hattori S, Yasuda T, Ishii K. Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan. Eur J Nucl Med Mol Imaging 2021. [PMID: 33934168 DOI: 10.1007/s00259-021-05365-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Matsuda S, Kawakubo H, Okamura A, Takahashi K, Toihata T, Takemura R, Mayanagi S, Takeuchi H, Watanabe M, Kitagawa Y. Prognostic Significance of Stratification Using Pathological Stage and Response to Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021. [PMID: 34142294 DOI: 10.1245/s10434-021-10221-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Matsumoto Y, Shiozaki A, Kosuga T, Kudou M, Shimizu H, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Konishi E, Otsuji E. Expression and Role of CFTR in Human Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021. [PMID: 33710504 DOI: 10.1245/s10434-021-09752-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Nakatani M, Migita K, Matsumoto S, Wakatsuki K, Ito M, Nakade H, Kunishige T, Kitano M, Kanehiro H. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy. Dis Esophagus 2017;30:1-7. [PMID: 28575242 DOI: 10.1093/dote/dox020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
24 Saeki H, Sohda M, Sakai M, Sano A, Shirabe K. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2020;4:490-7. [PMID: 33005843 DOI: 10.1002/ags3.12364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Hosoda K, Yamashita K, Tsuruta H, Moriya H, Mieno H, Ema A, Washio M, Watanabe M. Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy. Oncol Lett 2018;15:1200-10. [PMID: 29399174 DOI: 10.3892/ol.2017.7441] [Reference Citation Analysis]
26 Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, Yang Z, Zhou A. Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study. Cancer Manag Res 2021;13:2163-70. [PMID: 33688259 DOI: 10.2147/CMAR.S298360] [Reference Citation Analysis]
27 Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Taku H, Ohhara M, Takimoto T, Tanaka Y. A long-surviving patient with advanced esophageal basaloid squamous cell carcinoma treated only with radiotherapy: case report and literature review. BMC Gastroenterol 2017;17:151. [PMID: 29216832 DOI: 10.1186/s12876-017-0714-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
28 Masuike Y, Tanaka K, Makino T, Yamasaki M, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Mori M, Doki Y. Esophageal squamous cell carcinoma with low mitochondrial copy number has mesenchymal and stem-like characteristics, and contributes to poor prognosis. PLoS One 2018;13:e0193159. [PMID: 29447301 DOI: 10.1371/journal.pone.0193159] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
29 Baba Y, Baba H, Yamamoto S, Shimada H, Shibata T, Miyazaki T, Yoshikawa T, Nakajima Y, Tsuji Y, Shimokawa M, Kitagawa Y, Aiba K. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Dis Esophagus 2017;30:1-7. [PMID: 27001532 DOI: 10.1111/dote.12482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
30 Koyanagi K, Kanamori K, Ninomiya Y, Yatabe K, Higuchi T, Yamamoto M, Tajima K, Ozawa S. Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan. Cancers (Basel) 2020;13:E51. [PMID: 33375499 DOI: 10.3390/cancers13010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 2021;39:2803-15. [PMID: 34077237 DOI: 10.1200/JCO.20.03611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Seike J, Sawada T, Kawakita N, Yamamoto Y, Yuasa Y, Yamai H, Takachi H, Yoshida T, Tangoku A. A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP. Int J Surg Oncol 2011;2011:715623. [PMID: 22312520 DOI: 10.1155/2011/715623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
33 Makazu M, Kato K, Takisawa H, Yoshinaga S, Oda I, Saito Y, Mayahara H, Ito Y, Itami J, Hamaguchi T, Yamada Y, Shimada Y. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer. Dis Esophagus 2014;27:42-9. [PMID: 23442160 DOI: 10.1111/dote.12037] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
34 Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, Baba H. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World J Surg 2017;41:480-6. [PMID: 27637603 DOI: 10.1007/s00268-016-3649-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
35 Fukuda S, Miyata H, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway. Ann Surg Oncol 2015;22 Suppl 3:S1461-8. [PMID: 25808097 DOI: 10.1245/s10434-015-4522-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
36 Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Nakamura Y, Yamaue H. Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. Surg Today. 2017;47:65-73. [PMID: 27130464 DOI: 10.1007/s00595-016-1338-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
37 Yoshida N, Watanabe M, Baba Y, Iwagami S, Ishimoto T, Iwatsuki M, Sakamoto Y, Miyamoto Y, Ozaki N, Baba H. Estimation of physiologic ability and surgical stress (E-PASS) can assess short-term outcome after esophagectomy for esophageal cancer. Esophagus 2013;10:86-94. [DOI: 10.1007/s10388-013-0369-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Smithers BM, Thomson I. Neoadjuvant Chemotherapy or Chemoradiotherapy for Locally Advanced Esophageal Cancer. Thoracic Surgery Clinics 2013;23:509-23. [DOI: 10.1016/j.thorsurg.2013.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
39 Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol 2021;12:1-10. [PMID: 33708420 DOI: 10.21037/jgo-20-599] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Ninomiya I, Okamoto K, Tsukada T, Kinoshita J, Oyama K, Fushida S, Osugi H, Ohta T. Recurrence patterns and risk factors following thoracoscopic esophagectomy with radical lymph node dissection for thoracic esophageal squamous cell carcinoma. Mol Clin Oncol. 2016;4:278-284. [PMID: 26893875 DOI: 10.3892/mco.2015.688] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
41 Moaven O, Wang TN. Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West. Surg Clin North Am 2019;99:479-99. [PMID: 31047037 DOI: 10.1016/j.suc.2019.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci 2016;107:726-33. [PMID: 27015293 DOI: 10.1111/cas.12938] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
43 Minato T, Yamamoto Y, Seike J, Yoshida T, Yamai H, Takechi H, Yuasa Y, Furukita Y, Goto M, Bando Y. Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2013;20:209-217. [PMID: 22847125 DOI: 10.1245/s10434-012-2535-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
44 Zhang SS, Yang H, Xie X, Luo KJ, Wen J, Bella AE, Hu Y, Yang F, Fu JH. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies. Dis Esophagus. 2014;27:574-584. [PMID: 23621119 DOI: 10.1111/dote.12073] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
45 Kanda M, Koike M, Tanaka C, Kobayashi D, Hattori N, Hayashi M, Yamada S, Omae K, Fujiwara M, Kodera Y. Modified Systemic Inflammation Score is Useful for Risk Stratification After Radical Resection of Squamous Cell Carcinoma of the Esophagus. Ann Surg Oncol 2019;26:4773-81. [PMID: 31605344 DOI: 10.1245/s10434-019-07914-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
46 Sugimura K, Miyata H, Motoori M, Omori T, Fujiwara Y, Yano M. The Significance of SCC and CEA mRNA in the Pleural Cavity After Lymphadenectomy in Esophageal Cancer Patients who Underwent Preoperative Treatment. World J Surg 2018;42:749-57. [DOI: 10.1007/s00268-017-4203-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Ohkura Y, Shindoh J, Ueno M, Iizuka T, Udagawa H. Comparison of Outcome of Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer with Clinical Complete Response to Neoadjuvant Therapy. Ann Surg Oncol 2018;25:2428-33. [DOI: 10.1245/s10434-018-6437-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
48 Kataoka K, Nakamura K, Mizusawa J, Kato K, Eba J, Katayama H, Shibata T, Fukuda H. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis. European Journal of Surgical Oncology (EJSO) 2017;43:1956-61. [DOI: 10.1016/j.ejso.2017.06.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Akiyama Y, Iwaya T, Shioi Y, Endo F, Chiba T, Otsuka K, Nitta H, Koeda K, Mizuno M, Uesugi N, Kimura Y, Sasaki A. Effectiveness of neoadjuvant chemotherapy with cisplatin and irinotecan followed by surgery on small-cell carcinoma of the esophagus: A case report. Int J Surg Case Rep. 2015;17:121-125. [PMID: 26615446 DOI: 10.1016/j.ijscr.2015.11.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
50 Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, Iwagami S, Baba H. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol 2014;21:2838-44. [PMID: 24715216 DOI: 10.1245/s10434-014-3684-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
51 Onishi S, Tajika M, Tanaka T, Yamada K, Abe T, Higaki E, Hosoi T, Inaba Y, Muro K, Shimizu M, Niwa Y. Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma. J Clin Med 2020;9:E2974. [PMID: 32942595 DOI: 10.3390/jcm9092974] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
52 D’Journo XB, Thomas PA. Current management of esophageal cancer. J Thorac Dis. 2014;6 Suppl 2:S253-S264. [PMID: 24868443 DOI: 10.3978/j.issn.2072-1439.2014.04.16] [Cited by in F6Publishing: 52] [Reference Citation Analysis]
53 Klevebro F, Lindblad M, Johansson J, Lundell L, Nilsson M. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry. Br J Surg 2016;103:1864-73. [PMID: 27689845 DOI: 10.1002/bjs.10304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
54 Lim SH, Shim YM, Park SH, Kim HK, Choi YS, Ahn MJ, Park K, Zo JI, Sun JM. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. Cancer Res Treat 2017;49:816-23. [PMID: 27857024 DOI: 10.4143/crt.2016.417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
56 Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Aoki K, Mizoguchi Y, Kitano S, Yachida S, Shiba S, Kitagawa Y. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol 2020;16:1351-7. [PMID: 32396014 DOI: 10.2217/fon-2020-0189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
57 Kozuki R, Watanabe M, Toihata T, Takahashi K, Otake R, Okamura A, Imamura Y, Mine S. Treatment strategies and outcomes for elderly patients with locally advanced squamous cell carcinoma of the esophagus. Surg Today 2021. [PMID: 34331129 DOI: 10.1007/s00595-021-02348-9] [Reference Citation Analysis]
58 Yuda M, Yamashita K, Okamura A, Hayami M, Fukudome I, Toihata T, Imamura Y, Mine S, Ishizuka N, Watanabe M. Influence of Preoperative Oropharyngeal Microflora on the Occurrence of Postoperative Pneumonia and Survival in Patients Undergoing Esophagectomy for Esophageal Cancer. Ann Surg 2020;272:1035-43. [PMID: 30946087 DOI: 10.1097/SLA.0000000000003287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
59 Takahashi N, Umezawa R, Takanami K, Yamamoto T, Ishikawa Y, Kozumi M, Takeda K, Kadoya N, Jingu K. Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2018;129:161-5. [PMID: 29108779 DOI: 10.1016/j.radonc.2017.10.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
60 Kawakita Y, Motoyama S, Sato Y, Wakita A, Nagaki Y, Imai K, Minamiya Y. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy. World J Surg 2020;44:1559-68. [PMID: 31907570 DOI: 10.1007/s00268-019-05344-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Li B, Hu H, Zhang Y, Zhang J, Sun Y, Xiang J, Chen H. Esophageal squamous cell carcinoma patients with positive lymph nodes benefit from extended radical lymphadenectomy. The Journal of Thoracic and Cardiovascular Surgery 2019;157:1275-1283.e1. [DOI: 10.1016/j.jtcvs.2018.11.094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
62 Kano K, Yamada T, Yamamoto K, Komori K, Watanabe H, Takahashi K, Fujikawa H, Aoyama T, Numata M, Tamagawa H, Yukawa N, Rino Y, Masuda M, Ogata T, Oshima T. The Impact of Pretherapeutic Naples Prognostic Score on Survival in Patients with Locally Advanced Esophageal Cancer. Ann Surg Oncol 2021;28:4530-9. [PMID: 33423121 DOI: 10.1245/s10434-020-09549-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
63 Kaneko MK, Itai S, Yamada S, Kato Y. 47-mG2a: A Mouse IgG2a-Type of PcMab-47 Useful for Detecting Podocalyxin in Esophageal Cancers by Immunohistochemistry. Monoclon Antib Immunodiagn Immunother 2018;37:158-61. [PMID: 29630446 DOI: 10.1089/mab.2018.0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Sato Y, Motoyama S, Nanjo H, Wakita A, Yoshino K, Sasaki T, Nagaki Y, Liu J, Imai K, Saito H, Minamiya Y. CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2016;23:936-42. [PMID: 26464192 DOI: 10.1245/s10434-015-4909-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
65 Murakami M, Otsuka K, Goto S, Ariyoshi T, Yamashita T, Aoki T. Thoracoscopic and hand assisted laparoscopic esophagectomy with radical lymph node dissection for esophageal squamous cell carcinoma in the left lateral decubitus position: a single center retrospective analysis of 654 patients. BMC Cancer 2017;17:748. [PMID: 29126387 DOI: 10.1186/s12885-017-3743-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
66 Klevebro F, Ekman S, Nilsson M. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer - Review article. Surg Oncol. 2017;26:290-295. [PMID: 28807249 DOI: 10.1016/j.suronc.2017.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
67 Matsubara H. Advances in the surgical treatment of esophageal cancer since 1965. Ann Gastroenterol Surg 2020;4:243-9. [PMID: 32490339 DOI: 10.1002/ags3.12332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
68 Sun JM. Adjuvant Therapy for Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:168-71. [PMID: 32793447 DOI: 10.5090/kjtcs.2020.53.4.168] [Reference Citation Analysis]
69 Sugawara M, Katada C, Katada N, Takahashi K, Higuchi K, Komori S, Moriya H, Ishiyama H, Yamashita K, Sakuramoto S, Tanabe S, Koizumi W, Yago K. Retrospective evaluation of adverse events of neoadjuvant or induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal squamous cell carcinoma. Esophagus 2013;10:65-9. [DOI: 10.1007/s10388-013-0365-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Tryakin A, Pokataev I, Kononets P, Fedyanin M, Bokhyan V, Malikhova O, Minin K, Shogenov M, Stilidi I, Vybarava A, Davydov M, Tjulandin S. Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study. Jpn J Clin Oncol 2016;46:610-4. [PMID: 27052115 DOI: 10.1093/jjco/hyw039] [Reference Citation Analysis]
71 Ishibashi Y, Tsujimoto H, Hiraki S, Kumano I, Yaguchi Y, Horiguchi H, Nomura S, Ito N, Shinto E, Aosasa S, Yamamoto J, Ueno H. Prognostic Value of Preoperative Systemic Immunoinflammatory Measures in Patients with Esophageal Cancer. Ann Surg Oncol 2018;25:3288-99. [PMID: 30019304 DOI: 10.1245/s10434-018-6651-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
72 Okumura T, Yamaguchi T, Watanabe T, Nagata T, Shimada Y. Clinical Relevance of a Candidate Stem Cell Marker, p75 Neurotrophin Receptor (p75NTR) Expression in Circulating Tumor Cells. Adv Exp Med Biol 2017;994:247-54. [PMID: 28560678 DOI: 10.1007/978-3-319-55947-6_13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
73 Blencowe NS, Chana P, Whistance RN, Stevens D, Wong NACS, Falk SJ, Blazeby JM. Outcome Reporting in Neoadjuvant Surgical Trials: A Systematic Review of the Literature and Proposals for New Standards. JNCI Journal of the National Cancer Institute 2014;106:dju217-dju217. [DOI: 10.1093/jnci/dju217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
74 Zhao P, Yan W, Fu H, Lin Y, Chen KN. Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis. Thorac Cancer 2018;9:1048-55. [PMID: 29927075 DOI: 10.1111/1759-7714.12787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
75 Hashimoto M, Kitagami H, Niwa H, Kikkawa T, Ohuchi T, Takenouchi T, Hosokawa M. Prognosis and prognostic factors of esophageal spindle cell carcinoma treated by esophagectomy: a retrospective single-institution analysis. Esophagus. 2019;16:292-299. [PMID: 30937574 DOI: 10.1007/s10388-019-00667-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
76 Li XK, Fan QX. Progress in medication treatment of esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
77 Tahara M, Fuse N, Mizusawa J, Sato A, Nihei K, Kanato K, Kato K, Yamazaki K, Muro K, Takaishi H. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). Cancer Sci. 2015;106:1414-1420. [PMID: 26250827 DOI: 10.1111/cas.12764] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
78 Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T, Moriyama M, Shiraishi N, Inomata M. A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS One 2017;12:e0188098. [PMID: 29136005 DOI: 10.1371/journal.pone.0188098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
79 Yamauchi T, Fujishima F, Hashimoto M, Tsunokake J, Akaishi R, Gokon Y, Ueki S, Ozawa Y, Fukutomi T, Okamoto H, Sato C, Taniyama Y, Nakamura T, Nakaya N, Kamei T, Sasano H. Necroptosis in Esophageal Squamous Cell Carcinoma: An Independent Prognostic Factor and Its Correlation with Tumor-Infiltrating Lymphocytes. Cancers (Basel) 2021;13:4473. [PMID: 34503283 DOI: 10.3390/cancers13174473] [Reference Citation Analysis]
80 Motoori M, Yano M, Yasuda T, Miyata H, Peng YF, Yamasaki M, Shiraishi O, Tanaka K, Ishikawa O, Shiozaki H. Relationship between immunological parameters and the severity of neutropenia and effect of enteral nutrition on immune status during neoadjuvant chemotherapy on patients with advanced esophageal cancer. Oncology. 2012;83:91-100. [PMID: 22777298 DOI: 10.1159/000339694] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
81 Qiu ML, Lin JB, Li X, Luo RG, Liu B, Lin JW. Current state of esophageal cancer surgery in China: a national database analysis. BMC Cancer 2019;19:1064. [PMID: 31703631 DOI: 10.1186/s12885-019-6191-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
82 Imai T, Tanaka Y, Sato Y, Mase J, Suetsugu T, Fukada M, Yasufuku I, Iwata Y, Mori R, Imai H, Kato T, Okumura N, Matsuhashi N, Takahashi T, Futamura M, Yoshida K. The Role of Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Patients with Pathological Positive Lymph Nodes After Neoadjuvant Chemotherapy Followed by Esophagectomy: a Single Institute Retrospective Analysis. Indian J Surg Oncol 2021;:1-9. [PMID: 34483594 DOI: 10.1007/s13193-021-01419-0] [Reference Citation Analysis]
83 Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104:1455-1460. [PMID: 23991649 DOI: 10.1111/cas.12274] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 11.2] [Reference Citation Analysis]
84 Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, Imai K, Minamiya Y. SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. World J Surg Oncol 2021;19:105. [PMID: 33836789 DOI: 10.1186/s12957-021-02208-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Wong C, Law S. Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer. J Thorac Dis 2017;9:S773-80. [PMID: 28815073 DOI: 10.21037/jtd.2017.04.29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
86 Wang N, Jia Y, Wang J, Wang X, Bao C, Song Q, Tan B, Cheng Y. Prognostic significance of lymph node ratio in esophageal cancer. Tumour Biol 2015;36:2335-41. [PMID: 25412956 DOI: 10.1007/s13277-014-2840-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
87 Ishibashi Y, Tsujimoto H, Hiraki S, Kouzu K, Tsuchiya S, Itazaki Y, Yaguchi Y, Horiguchi H, Nomura S, Ito N, Shinto E, Kishi Y, Ueno H. Predictive value of immuno-inflammatory and nutritional measures modulated by neoadjuvant chemotherapy on the response of neoadjuvant chemotherapy and long-term outcomes in patients with esophageal cancer. Oncol Lett 2020;19:487-97. [PMID: 31897162 DOI: 10.3892/ol.2019.11122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
88 Tang H, Tan L, Shen Y, Wang H, Lin M, Feng M, Xu S, Guo W, Qian C, Liu T, Zeng Z, Hou Y, Yu Z, Jiang H, Li Z, Chen C, Lian C, Du M, Li H, Xie D, Yin J, Zhao N, Wang Q. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596). BMC Cancer 2017;17:450. [PMID: 28659128 DOI: 10.1186/s12885-017-3446-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
89 Yuda M, Nishikawa K, Ishikawa Y, Takahashi K, Kurogochi T, Tanaka Y, Matsumoto A, Tanishima Y, Mitsumori N, Ikegami T. Intraoperative nerve monitoring during esophagectomy reduces the risk of recurrent laryngeal nerve palsy. Surg Endosc 2021. [PMID: 34494155 DOI: 10.1007/s00464-021-08716-3] [Reference Citation Analysis]
90 Okumura T, Kojima H, Miwa T, Sekine S, Hashimoto I, Hojo S, Nagata T, Shimada Y. The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma. World J Surg Oncol 2016;14:228. [PMID: 27565418 DOI: 10.1186/s12957-016-0985-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
91 Han J, Wang Z, Liu C. Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis. Future Oncol 2021;17:2257-74. [PMID: 33739165 DOI: 10.2217/fon-2021-0021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Tajima K, Shimada H, Nishi T, Kamei Y, Koyanagi K, Makuuchi H. Distal gastric tube resection with preservation of the right gastroepiploic artery for gastric tube cancer: a case report. Surg Case Rep 2021;7:266. [PMID: 34928456 DOI: 10.1186/s40792-021-01340-2] [Reference Citation Analysis]
93 Takahari D, Shinozaki E, Wakatsuki T, Ooki A, Ozaka M, Suzuki T, Nakayama I, Osumi H, Kamiimabeppu D, Sato T, Ogura M, Suenaga M, Chin K, Yamaguchi K. Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. Int J Clin Oncol 2021;26:335-44. [PMID: 33085057 DOI: 10.1007/s10147-020-01806-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 Booka E, Haneda R, Ishii K, Tsushima T, Yasui H, Tsubosa Y. The Negative Impact of Preoperative Chemotherapy on Survival After Esophagectomy for Vulnerable Elderly Patients with Esophageal Cancer. Ann Surg Oncol 2021;28:1786-95. [PMID: 32876790 DOI: 10.1245/s10434-020-09072-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Habbous S, Yermakhanova O, Forster K, Holloway CMB, Darling G. Variation in Diagnosis, Treatment, and Outcome of Esophageal Cancer in a Regionalized Care System in Ontario, Canada. JAMA Netw Open 2021;4:e2126090. [PMID: 34546371 DOI: 10.1001/jamanetworkopen.2021.26090] [Reference Citation Analysis]
96 Nagata K, Tsujimoto H, Nagata H, Harada M, Ito N, Nomura S, Horiguchi H, Hiraki S, Aosasa S, Hase K, Ueno H. Nutritional benefit of laparoscopic jejunostomy during neoadjuvant chemotherapy for obstructing esophageal cancer. Mol Clin Oncol 2019;11:612-6. [PMID: 31692945 DOI: 10.3892/mco.2019.1938] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Li S, Liu H, Diao C, Wang X, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Li W, Han X. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget 2017;8:36339-53. [PMID: 28423740 DOI: 10.18632/oncotarget.16193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
98 Hiura A, Yoshino K, Maeda T, Nagai K, Oaku S, Yamashita C, Kato M, Uehara J, Fujisawa Y. Continued Chemotherapy After Concurrent Chemoradiotherapy Improves Treatment Outcomes for Unresectable Cutaneous Squamous Cell Carcinoma: An Analysis of 13 Cases. Front Med (Lausanne) 2019;6:207. [PMID: 31620441 DOI: 10.3389/fmed.2019.00207] [Reference Citation Analysis]
99 Ui T, Fujii H, Hosoya Y, Nagase M, Mieno MN, Mori M, Zuiki T, Saito S, Kurashina K, Haruta H, Matsumoto S, Niki T, Lefor A, Yasuda Y. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus. Dis Esophagus 2015;28:180-7. [PMID: 24529073 DOI: 10.1111/dote.12187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
100 Matsunaga T, Saito H, Fukumoto Y, Shimizu S, Kono Y, Murakami Y, Shishido Y, Miyatani K, Yamamoto M, Tokuyasu N, Takano S, Sakamoto T, Honjo S, Fujiwara Y. The postoperative platelet distribution width is useful for predicting the prognosis in patients with esophageal squamous cell carcinoma. Surg Today 2020;50:123-33. [DOI: 10.1007/s00595-019-01860-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
101 Zhou C, Zhang L, Xu P. Growth inhibition and chemo-radiosensitization of esophageal squamous cell carcinoma by survivin-shRNA lentivirus transfection. Oncol Lett 2018;16:4813-20. [PMID: 30250546 DOI: 10.3892/ol.2018.9280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
102 Kadota T, Hatogai K, Yano T, Fujita T, Kojima T, Daiko H, Fujii S. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients. Cancer Sci 2018;109:2046-55. [PMID: 29601131 DOI: 10.1111/cas.13596] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
103 Yamashita H, Seto Y, Takenaka R, Okuma K, Kiritooshi T, Mori K, Yamada K, Fukuda T, Kaminishi M, Abe O, Nakagawa K. Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study. PLoS One 2017;12:e0177133. [PMID: 28486551 DOI: 10.1371/journal.pone.0177133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
104 Miwa T, Kanda M, Koike M, Iwata N, Tanaka H, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Fujii T, Fujiwara M, Kodera Y. Identification of NCCRP1 as an epigenetically regulated tumor suppressor and biomarker for malignant phenotypes of squamous cell carcinoma of the esophagus. Oncol Lett 2017;14:4822-8. [PMID: 29085486 DOI: 10.3892/ol.2017.6753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
105 Hayashi M, Okano N, Mizutani T. Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer. JAMA Oncol 2021. [PMID: 34967841 DOI: 10.1001/jamaoncol.2021.6840] [Reference Citation Analysis]
106 Li X, Wang W, Zhou Y, Yang D, Wu J, Zhang B, Wu Z, Tang J. Efficacy comparison of transcervical video-assisted mediastinoscopic lymphadenectomy combined with left transthoracic esophagectomy versus right transthoracic esophagectomy for esophageal cancer treatment. World J Surg Oncol. 2018;16:25. [PMID: 29426329 DOI: 10.1186/s12957-017-1268-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
107 Yoshida N, Nakamura K, Kuroda D, Baba Y, Miyamoto Y, Iwatsuki M, Hiyoshi Y, Ishimoto T, Imamura Y, Watanabe M, Baba H. Preoperative Smoking Cessation is Integral to the Prevention of Postoperative Morbidities in Minimally Invasive Esophagectomy. World J Surg 2018;42:2902-9. [DOI: 10.1007/s00268-018-4572-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
108 Matsuda S, Niihara M, Tsubosa Y, Sato H, Takebayashi K, Kawamorita K, Mori K, Tsushima T, Yasui H, Takeuchi H, Kitagawa Y. Clinical significance of postoperative recovery of serum albumin levels in patients with esophageal cancer who underwent transthoracic esophagectomy. Surg Today 2016;46:1138-45. [DOI: 10.1007/s00595-015-1300-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
109 Yuan M, Bao Y, Ma Z, Men Y, Wang Y, Hui Z. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. Front Oncol 2021;11:628706. [PMID: 33777777 DOI: 10.3389/fonc.2021.628706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Yoshikawa R, Tsujimura T, Tao L, Kamikonya N, Fujiwara Y. The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy. BMC Cancer. 2012;12:461. [PMID: 23046527 DOI: 10.1186/1471-2407-12-461] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
111 Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Taniki T, Ura T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Taira K, Seki S, Nakamura T, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci 2014;105:1189-95. [PMID: 25041052 DOI: 10.1111/cas.12486] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
112 Kanemura T, Makino T, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. Distribution patterns of metastases in recurrent laryngeal nerve lymph nodes in patients with squamous cell esophageal cancer. Dis Esophagus 2017;30:1-7. [PMID: 27630087 DOI: 10.1111/dote.12527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
113 Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Omae K, Kodera Y. Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations. Ann Surg Oncol 2019;26:3718-26. [PMID: 31197518 DOI: 10.1245/s10434-019-07512-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
114 Yoshimoto T, Kobayashi S, Kanetaka K, Kobayashi K, Nagata Y, Morita M, Isagawa Y, Kinoshita N, Takatsuki M, Eguchi S. Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature. Surg Case Rep 2018;4:18. [PMID: 29455418 DOI: 10.1186/s40792-018-0425-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
115 Fukaya M, Yokoyama Y, Usui H, Fujieda H, Sakatoku Y, Takahashi T, Miyata K, Niikura M, Sugimoto T, Asahara T, Nagino M, Ebata T. Impact of synbiotics treatment on bacteremia induced during neoadjuvant chemotherapy for esophageal cancer: A randomised controlled trial. Clin Nutr 2021;40:5781-91. [PMID: 34775221 DOI: 10.1016/j.clnu.2021.10.004] [Reference Citation Analysis]
116 Abe S, Oguma J, Nonaka S, Suzuki H, Yoshinaga S, Oda I, Saito Y, Daiko H. Novel hybrid endoscopy-assisted larynx-preserving esophagectomy for cervical esophageal cancer (with video). Jpn J Clin Oncol 2021;51:1171-5. [PMID: 33855445 DOI: 10.1093/jjco/hyab045] [Reference Citation Analysis]
117 Fujiwara Y, Lee S, Kishida S, Hashiba R, Gyobu K, Takemura M, Osugi H. Safety and feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy for esophageal cancer. Surg Today 2017;47:1356-60. [PMID: 28386749 DOI: 10.1007/s00595-017-1526-6] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
118 Zhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS One 2018;13:e0202185. [PMID: 30138325 DOI: 10.1371/journal.pone.0202185] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
119 Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol 2018;23:466-72. [DOI: 10.1007/s10147-018-1239-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
120 Saeki H, Tsutsumi S, Yukaya T, Tajiri H, Tsutsumi R, Nishimura S, Nakaji Y, Kudou K, Akiyama S, Kasagi Y, Nakashima Y, Sugiyama M, Sonoda H, Ohgaki K, Oki E, Yasumatsu R, Nakashima T, Morita M, Maehara Y. Clinicopathological Features of Cervical Esophageal Cancer: Retrospective Analysis of 63 Consecutive Patients Who Underwent Surgical Resection. Ann Surg 2017;265:130-6. [PMID: 28009737 DOI: 10.1097/SLA.0000000000001599] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
121 Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 2013;43:752-5. [PMID: 23625063 DOI: 10.1093/jjco/hyt061] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 14.0] [Reference Citation Analysis]
122 Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018;36:2796-2803. [PMID: 30089078 DOI: 10.1200/jco.2018.79.1483] [Cited by in Crossref: 142] [Cited by in F6Publishing: 117] [Article Influence: 35.5] [Reference Citation Analysis]
123 Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, Imamura Y, Ohgaki K, Ito S, Kimura Y, Egashira A, Oki E, Morita M, Maehara Y. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today 2016;46:261-7. [PMID: 25740123 DOI: 10.1007/s00595-015-1144-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
124 Tamaoki M, Komatsuzaki R, Komatsu M, Minashi K, Aoyagi K, Nishimura T, Chiwaki F, Hiroki T, Daiko H, Morishita K, Sakai Y, Seno H, Chiba T, Muto M, Yoshida T, Sasaki H. Multiple roles of single-minded 2 in esophageal squamous cell carcinoma and its clinical implications. Cancer Sci 2018;109:1121-34. [PMID: 29427302 DOI: 10.1111/cas.13531] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
125 Yoshida N, Watanabe M, Baba Y, Ishimoto T, Iwagami S, Sakamoto Y, Miyamoto Y, Karashima R, Baba H. Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer. Dis Esophagus 2014;27:374-9. [PMID: 23927456 DOI: 10.1111/dote.12117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
126 Ogino S, Konishi H, Ichikawa D, Matsubara D, Shoda K, Arita T, Kosuga T, Komatsu S, Shiozaki A, Okamoto K, Kishimoto M, Otsuji E. Glutathione S-transferase Pi 1 is a valuable predictor for cancer drug resistance in esophageal squamous cell carcinoma. Cancer Sci 2019;110:795-804. [PMID: 30499150 DOI: 10.1111/cas.13896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
127 Nakagawa A, Nakamura T, Oshikiri T, Hasegawa H, Yamamoto M, Kanaji S, Matsuda Y, Yamashita K, Matsuda T, Sumi Y, Suzuki S, Kakeji Y. The Surgical Apgar Score Predicts Not Only Short-Term Complications But Also Long-Term Prognosis After Esophagectomy. Ann Surg Oncol 2017;24:3934-46. [PMID: 28986819 DOI: 10.1245/s10434-017-6103-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
128 Zhu JF, Feng XY, Zhang XW, Wen YS, Lin P, Cai L, Zhang LJ. Time distribution of recurrence risk of oesophageal squamous cell carcinoma with complete resection (R0) in a Chinese population. Eur J Cardiothorac Surg 2015;48:899-905. [PMID: 25899517 DOI: 10.1093/ejcts/ezv147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
130 Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2009;2:9. [PMID: 19236713 DOI: 10.1186/1756-8722-2-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
131 Utsunomiya S, Uehara K, Kurimoto T, Hirose K, Fukaya M, Takahashi Y, Taguchi Y, Itatsu K, Nagino M. Synchronous rectal and esophageal cancer treated with chemotherapy followed by two-stage resection. World J Clin Cases 2013; 1(2): 87-91 [PMID: 24303474 DOI: 10.12998/wjcc.v1.i2.87] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Voeten DM, den Bakker CM, Heineman DJ, Ket JCF, Daams F, van der Peet DL. Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature. World J Surg 2019;43:1271-85. [PMID: 30607604 DOI: 10.1007/s00268-018-04901-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
133 Yamashita K, Makino T, Miyata H, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. Postoperative Infectious Complications are Associated with Adverse Oncologic Outcomes in Esophageal Cancer Patients Undergoing Preoperative Chemotherapy. Ann Surg Oncol 2016;23:2106-14. [PMID: 26753750 DOI: 10.1245/s10434-015-5045-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
134 Kubo K, Wadasaki K, Shinozaki K. Treatment outcomes according to the macroscopic tumor type in locally advanced esophageal squamous cell carcinoma treated by chemoradiotherapy. Jpn J Radiol 2019;37:341-9. [DOI: 10.1007/s11604-019-00814-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Nakajima M, Muroi H, Kikuchi M. The significance of surgery following concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Dis 2018;10:S3843-5. [PMID: 30631494 DOI: 10.21037/jtd.2018.09.58] [Reference Citation Analysis]
136 Karashima R, Watanabe M, Imamura Y, Ida S, Baba Y, Iwagami S, Miyamoto Y, Sakamoto Y, Yoshida N, Baba H. Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer. Surg Today. 2015;45:471-477. [PMID: 24969050 DOI: 10.1007/s00595-014-0965-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
137 Fan N, Wang Z, Zhou C, Bludau M, Contino G, Zhao Y, Bruns C. Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis. EClinicalMedicine 2021;42:101183. [PMID: 34805809 DOI: 10.1016/j.eclinm.2021.101183] [Reference Citation Analysis]
138 Zhang H, Guo XW, Yin XX, Liu YC, Ji SJ. Nomogram-Integrated C-Reactive Protein/Albumin Ratio Predicts Efficacy And Prognosis In Patients With Thoracic Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy. Cancer Manag Res 2019;11:9459-68. [PMID: 31819611 DOI: 10.2147/CMAR.S228113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
139 Song T, Yao Q, Qu J, Zhang H, Zhao Y, Qin J, Feng W, Zhang S, Han X, Wang S, Yan X, Li H. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma. Eur Radiol 2021;31:1391-400. [PMID: 32901300 DOI: 10.1007/s00330-020-07248-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 van den Boorn HG, Stroes CI, Zwinderman AH, Eshuis WJ, Hulshof MCCM, van Etten-Jamaludin FS, Sprangers MAG, van Laarhoven HWM. Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;154:103069. [PMID: 32818901 DOI: 10.1016/j.critrevonc.2020.103069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
141 Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016;10:383-392. [PMID: 26560689 DOI: 10.1586/17474124.2016.1116936] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
142 Hong ZN, Weng K, Peng K, Chen Z, Lin J, Kang M. Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study. Front Oncol 2021;11:797426. [PMID: 34970498 DOI: 10.3389/fonc.2021.797426] [Reference Citation Analysis]
143 Haneda R, Hiramatsu Y, Kawata S, Honke J, Soneda W, Matsumoto T, Morita Y, Kikuchi H, Kamiya K, Takeuchi H. Survival impact of perioperative changes in prognostic nutritional index levels after esophagectomy. Esophagus 2021. [PMID: 34546503 DOI: 10.1007/s10388-021-00883-5] [Reference Citation Analysis]
144 Wakefield CJ, Hamati F, Karush JM, Arndt AT, Geissen N, Liptay MJ, Borgia JA, Basu S, Seder CW. Sarcopenia after induction therapy is associated with reduced survival in patients undergoing esophagectomy for locally-advanced esophageal cancer. J Thorac Dis 2021;13:861-9. [PMID: 33717559 DOI: 10.21037/jtd-20-2608] [Reference Citation Analysis]
145 Nakao R, Konishi E, Fujiwara H, Otsuji E, Yokota I, Urata Y, Yanagisawa A. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy. Int J Surg Pathol 2019;27:713-21. [PMID: 31203677 DOI: 10.1177/1066896919855760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Shishido Y, Saito H, Shimizu S, Kono Y, Murakami Y, Miyatani K, Matsunaga T, Yamamoto M, Fukumoto Y, Honjo S, Fujiwara Y. Prognostic significance of platelet × C-reactive protein multiplier in patients with esophageal squamous cell carcinoma. Surg Today 2020;50:185-92. [DOI: 10.1007/s00595-019-01865-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Emi M, Hihara J, Hamai Y, Furukawa T, Ibuki Y, Okada M. Clinicopathologic Features of Submucosal Esophageal Squamous Cell Carcinoma. Ann Thorac Surg 2017;104:1858-64. [PMID: 29033014 DOI: 10.1016/j.athoracsur.2017.06.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
148 Kunishige T, Migita K, Matsumoto S, Wakatsuki K, Nakade H, Miyao S, Kuniyasu H, Sho M. Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer. Oncol Lett 2020;20:2919-27. [PMID: 32782608 DOI: 10.3892/ol.2020.11840] [Reference Citation Analysis]
149 Onodera Y, Nakano T, Heishi T, Sakurai T, Taniyama Y, Sato C, Ohuchi N, Kamei T. Bilateral approach for thoracoscopic esophagectomy with lymph node dissection in the dorsal area of the thoracic aorta in patients with esophageal cancer: A report of two cases. Int J Surg Case Rep 2017;31:154-8. [PMID: 28161685 DOI: 10.1016/j.ijscr.2017.01.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
150 Jin Z, Chen D, Chen M, Wang C, Zhang B, Zhang J, Zhu C, Shen J. (Neo)adjuvant Chemoradiotherapy is Beneficial to the Long-term Survival of Locally Advanced Esophageal Squamous Cell Carcinoma: A Network Meta-analysis. World J Surg 2021. [PMID: 34482411 DOI: 10.1007/s00268-021-06301-2] [Reference Citation Analysis]
151 Triantafyllou T, Wijnhoven B. Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Ann Gastroenterol Surg 2020;4:352-9. [PMID: 32724878 DOI: 10.1002/ags3.12350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Cuesta MA, van der Peet DL, Gisbertz SS, Straatman J. Mediastinal lymphadenectomy for esophageal cancer: Differences between two countries, Japan and the Netherlands. Ann Gastroenterol Surg 2018;2:176-81. [PMID: 29863178 DOI: 10.1002/ags3.12172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
153 Komatsu M, Sasaki H. DNA methylation is a key factor in understanding differentiation phenotype in esophageal squamous cell carcinoma. Epigenomics. 2014;6:567-569. [PMID: 25531249 DOI: 10.2217/epi.14.56] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
154 Nishimura T, Tamaoki M, Komatsuzaki R, Oue N, Taniguchi H, Komatsu M, Aoyagi K, Minashi K, Chiwaki F, Shinohara H, Tachimori Y, Yasui W, Muto M, Yoshida T, Sakai Y, Sasaki H. SIX1 maintains tumor basal cells via transforming growth factor-β pathway and associates with poor prognosis in esophageal cancer. Cancer Sci 2017;108:216-25. [PMID: 27987372 DOI: 10.1111/cas.13135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
155 Luo Y, Wang X, Yu J, Zhang B, Li M. Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma–a review. Tumor Biol 2016;37:14443-50. [DOI: 10.1007/s13277-016-5373-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Ozawa Y, Kamei T, Nakano T, Taniyama Y, Miyagi S, Ohuchi N. Characteristics of Postoperative Recurrence in Lymph Node-Negative Superficial Esophageal Carcinoma. World J Surg. 2016;40:1663-1671. [PMID: 26908240 DOI: 10.1007/s00268-016-3454-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
157 Nakamura K, Shibata T, Takashima A, Yamamoto S, Fukuda H. Evaluation of Three Definitions of Progression-free Survival in Preoperative Cancer Therapy (JCOG0801-A). Japanese Journal of Clinical Oncology 2012;42:896-902. [DOI: 10.1093/jjco/hys122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
158 Shah MA, Kennedy EB, Catenacci DV, Deighton DC, Goodman KA, Malhotra NK, Willett C, Stiles B, Sharma P, Tang L, Wijnhoven BPL, Hofstetter WL. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol 2020;38:2677-94. [PMID: 32568633 DOI: 10.1200/JCO.20.00866] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 9.5] [Reference Citation Analysis]
159 Osumi H, Yoshio T, Chin K, Ogura M, Kumekawa Y, Suenaga M, Matsusaka S, Shinozaki E, Miyamoto Y, Morishige K, Ishiyama A, Hirasawa T, Tsuchida T, Yamamoto Y, Fujisaki J, Igarashi M, Mizunuma N. Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer. Gastric Cancer 2016;19:625-30. [DOI: 10.1007/s10120-015-0517-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
160 Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, Ishimoto T, Baba Y, Mimori K, Baba H. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer. 2012;107:1233-1238. [PMID: 22955852 DOI: 10.1038/bjc.2012.396] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
161 Fujita H. History of lymphadenectomy for esophageal cancer and the future prospects for esophageal cancer surgery. Surg Today 2015;45:140-9. [PMID: 24519395 DOI: 10.1007/s00595-014-0841-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
162 Okamura A, Watanabe M, Kozuki R, Toihata T, Takahashi K, Imamura Y, Mine S. Significance of Intramural Metastasis in Patients with Esophageal Squamous Cell Carcinoma: An Indicator of Aggressive Cancer Behavior. World J Surg 2019;43:1997-2005. [PMID: 30993389 DOI: 10.1007/s00268-019-05004-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
163 Maruyama S, Kawaguchi Y, Akaike H, Shoda K, Saito R, Shimizu H, Furuya S, Hosomura N, Amemiya H, Kawaida H, Sudo M, Inoue S, Kono H, Ichikawa D. Postoperative Complications have Minimal Impact on Long-Term Prognosis in Immunodeficient Patients with Esophageal Cancer. Ann Surg Oncol 2020;27:3064-70. [PMID: 32048090 DOI: 10.1245/s10434-020-08245-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Matsuda S, Takeuchi H, Kawakubo H, Takemura R, Maeda Y, Hirata Y, Kaburagi T, Egawa T, Nishi T, Ogura M, Miyasho T, Okamura A, Mayanagi S, Fukuda K, Nakamura R, Irino T, Wada N, Kitagawa Y. Validation Study of Fibrinogen and Albumin Score in Esophageal Cancer Patients Who Underwent Esophagectomy: Multicenter Prospective Cohort Study. Ann Surg Oncol 2021;28:774-84. [PMID: 32737701 DOI: 10.1245/s10434-020-08958-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
165 Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261 [PMID: 33959478 DOI: 10.5306/wjco.v12.i4.249] [Reference Citation Analysis]
166 Kouzu K, Tsujimoto H, Ishibashi Y, Shinada H, Oikawa I, Kishi Y, Shinomiya N, Ueno H. Preoperative Fall Risk Assessment Score as a Prognostic Factor in Esophageal Cancer Patients after Esophagectomy. J Clin Med 2021;10:5966. [PMID: 34945262 DOI: 10.3390/jcm10245966] [Reference Citation Analysis]
167 Wan Z, Huang Z, Chen L. Survival predictors associated with signet ring cell carcinoma of the esophagus (SRCCE): A population-based retrospective cohort study. PLoS One 2017;12:e0181845. [PMID: 28746362 DOI: 10.1371/journal.pone.0181845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
168 Ozawa Y, Nakano T, Taniyama Y, Sakurai T, Onodera Y, Kamiya K, Hikage M, Sato C, Takaya K, Konno T, Unno M, Kamei T. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy. Esophagus 2019;16:345-51. [PMID: 30980203 DOI: 10.1007/s10388-019-00670-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
169 Ichikawa H, Kosugi SI, Kanda T, Yajima K, Ishikawa T, Hanyu T, Muneoka Y, Otani T, Nagahashi M, Sakata J, Kobayashi T, Kameyama H, Wakai T. Surgical and long-term outcomes following oesophagectomy in oesophageal cancer patients with comorbidity. Int J Surg 2016;36:212-8. [PMID: 27810380 DOI: 10.1016/j.ijsu.2016.10.041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
170 Morimoto Y, Kawakubo H, Ishikawa A, Matsuda S, Hijikata N, Ando M, Mayanagi S, Irino T, Nakamura R, Wada N, Tsuji T, Kitagawa Y. Short-term outcomes of robot-assisted minimally invasive esophagectomy with extended lymphadenectomy for esophageal cancer compared with video-assisted minimally invasive esophagectomy: A single-center retrospective study. Asian J Endosc Surg 2021. [PMID: 34637190 DOI: 10.1111/ases.12992] [Reference Citation Analysis]
171 Baba Y, Watanabe M, Shigaki H, Iwagami S, Ishimoto T, Iwatsuki M, Baba H. Negative lymph-node count is associated with survival in patients with resected esophageal squamous cell carcinoma. Surgery 2013;153:234-41. [DOI: 10.1016/j.surg.2012.08.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
172 Noshiro H, Urata M, Ikeda O, Iwasaki H, Nabae T, Uchiyama A, Nagai E, Tanaka M. Triangulating stapling technique for esophagogastrostomy after minimally invasive esophagectomy. Surgery 2013;154:604-10. [PMID: 23859308 DOI: 10.1016/j.surg.2013.04.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
173 Konishi H, Fujiwara H, Shiozaki A, Hiramoto H, Kosuga T, Komatsu S, Ichikawa D, Okamoto K, Otsuji E. Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy. Int J Clin Oncol 2016;21:95-101. [PMID: 26194809 DOI: 10.1007/s10147-015-0875-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
174 Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, Gong L, Yu H, Yang H, Liu J, Lei T, Zhao Q, Mao W. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget 2016;7:50624-34. [PMID: 27244882 DOI: 10.18632/oncotarget.9562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
175 Kataoka A, Yamada K, Kawamura YI. ASO Author Reflections: Serine Protease 27 is a Novel Prognostic Indicator for Esophageal Squamous Cell Carcinoma with Preoperative Treatment. Ann Surg Oncol 2021;28:5382-3. [PMID: 33454876 DOI: 10.1245/s10434-020-09580-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Mine S, Watanabe M, Kumagai K, Okamura A, Yamashita K, Hayami M, Yuda M, Imamura Y, Ishizuka N. Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus. British Journal of Surgery 2018;105:1793-8. [DOI: 10.1002/bjs.10960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
177 Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 2019;3:269-75. [PMID: 31131355 DOI: 10.1002/ags3.12243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
178 Konishi H, Fujiwara H, Itoh H, Shiozaki A, Arita T, Kosuga T, Morimura R, Komatsu S, Ichikawa D, Okamoto K, Otsuji E. Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma. Oncol Lett 2018;15:658-64. [PMID: 29391892 DOI: 10.3892/ol.2017.7345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
179 Li Y, Huang HC, Chen LQ, Xu LY, Li EM, Zhang JJ. Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis. Surg Oncol 2017;26:460-72. [PMID: 29113666 DOI: 10.1016/j.suronc.2017.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
180 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 34.5] [Reference Citation Analysis]
181 Li B, Zhang Y, Miao L, Ma L, Luo X, Zhang Y, Ye T, Li H, Zhang J, Li Y, Zhao K, Fan M, Zhu Z, Wang J, Xu J, Deng Y, Lu Q, Li H, Zhang Y, Pan Y, Liu S, Shao L, Sun Y, Xiang J, Hu H, Chen H. Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial. J Thorac Oncol 2021;16:310-7. [PMID: 33307192 DOI: 10.1016/j.jtho.2020.10.157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
182 Katada C, Sugawara M, Hara H, Fujii H, Nakajima TE, Ando T, Kojima T, Watanabe A, Sakamoto Y, Ishikawa H, Hosokawa A, Hamamoto Y, Muto M, Tahara M, Koizumi W. A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. Jpn J Clin Oncol 2021;51:199-204. [PMID: 33147611 DOI: 10.1093/jjco/hyaa190] [Reference Citation Analysis]
183 Sugawara M, Katada C, Komatsu T, Takahashi K, Azuma M, Higuchi K, Koizumi W, Atsuda K. Association between pharmacokinetic variables and neutropenia after treatment with docetaxel, cisplatin, and 5-fluorouracil in patients with esophageal squamous cell carcinoma. Esophagus 2015;12:209-18. [DOI: 10.1007/s10388-014-0468-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Han L, Jia Y, Song Q, Wang N, Wang J, Bai B, Chen X, Wang C, Cheng Y. Prognostic significance of preoperative absolute peripheral monocyte count in esophageal squamous cell carcinoma: Preoperative AMC and ESCC outcomes. Dis Esophagus 2016;29:740-6. [DOI: 10.1111/dote.12401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
185 Yang H, Fu JH. Progress in surgery-based multimodality therapy for resectable esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3471-3475 [DOI: 10.11569/wcjd.v20.i35.3471] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
186 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
187 Hayashi M, Takeuchi H, Nakamura R, Suda K, Wada N, Kawakubo H, Kitagawa Y. Determination of the optimal surgical procedure by identifying risk factors for pneumonia after transthoracic esophagectomy. Esophagus 2020;17:50-8. [PMID: 31501982 DOI: 10.1007/s10388-019-00692-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Ohtsuka M, Yamamoto H, Masuzawa T, Takahashi H, Uemura M, Haraguchi N, Nishimura J, Hata T, Yamasaki M, Miyata H, Takemasa I, Mizushima T, Takiguchi S, Doki Y, Mori M. C4.4A expression is associated with a poor prognosis of esophageal squamous cell carcinoma. Ann Surg Oncol 2013;20:2699-705. [PMID: 23435632 DOI: 10.1245/s10434-013-2900-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
189 Momose K, Yamasaki M, Tanaka K, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. Oncol Lett 2017;14:958-64. [PMID: 28693258 DOI: 10.3892/ol.2017.6215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
190 Zhang X, Yang Y, Sun Y, Ye B, Guo X, Mao T, Hua R, Li B, Gu H, Liu J, Li Z. Adjuvant therapy for pathological T3N0M0 esophageal squamous cell carcinoma. J Thorac Dis 2019;11:2512-22. [PMID: 31372288 DOI: 10.21037/jtd.2019.05.70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
191 Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Omae K, Kodera Y. Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. BMC Surg. 2019;19:143. [PMID: 31615499 DOI: 10.1186/s12893-019-0617-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
192 Kanie Y, Okamura A, Maruyama S, Sakamoto K, Fujiwara D, Kanamori J, Imamura Y, Watanabe M. Clinical Significance of Serum Squamous Cell Carcinoma Antigen for Patients with Recurrent Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021. [PMID: 33839977 DOI: 10.1245/s10434-021-09945-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
193 Hara T, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Matsuura N, Mori M, Doki Y. Effect of c-Met and CD44v6 Expression in Resistance to Chemotherapy in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2019;26:899-906. [PMID: 30610559 DOI: 10.1245/s10434-018-07126-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
194 Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Inoue M, Yamamura T. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep 2012;28:446-52. [PMID: 22664791 DOI: 10.3892/or.2012.1847] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
195 Montagnani F, Fornaro L, Frumento P, Vivaldi C, Falcone A, Fioretto L. Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis. Crit Rev Oncol Hematol 2017;114:24-32. [PMID: 28477744 DOI: 10.1016/j.critrevonc.2017.03.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
196 Nakajima Y, Kawada K, Tokairin Y, Hoshino A, Miyawaki Y, Okada T, Miyake S, Kawano T. “Larynx-preserving surgery” for cervical esophageal carcinoma can preserve the vocal function and improve the clinical outcome. Esophagus 2017;14:76-83. [DOI: 10.1007/s10388-016-0547-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
197 Ide S, Toiyama Y, Shimura T, Kawamura M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Mohri Y, Kusunoki M. Angiopoietin-Like Protein 2 Acts as a Novel Biomarker for Diagnosis and Prognosis in Patients with Esophageal Cancer. Ann Surg Oncol 2015;22:2585-92. [PMID: 25564164 DOI: 10.1245/s10434-014-4315-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
198 Hagi T, Makino T, Yamasaki M, Tanaka K, Nishida N, Sakai D, Motoori M, Kimura Y, Satoh T, Mori M, Doki Y. Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. Ann Surg Oncol 2019;26:4754-64. [DOI: 10.1245/s10434-019-07744-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
199 Hirata A, Hayano K, Ohira G, Imanishi S, Hanaoka T, Toyozumi T, Murakami K, Aoyagi T, Shuto K, Matsubara H. Volumetric Histogram Analysis of Apparent Diffusion Coefficient as a Biomarker to Predict Survival of Esophageal Cancer Patients. Ann Surg Oncol 2020;27:3083-9. [PMID: 32100222 DOI: 10.1245/s10434-020-08270-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Xing W, Zhao L, Zheng Y, Liu B, Liu X, Li T, Zhang Y, Ma B, Yang Y, Shang Y, Fu X, Liang G, Yuan D, Qu J, Chai X, Zhang H, Wang Z, Lin H, Liu L, Ren X, Zhang J, Gao Q. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study. Front Immunol 2021;12:772450. [DOI: 10.3389/fimmu.2021.772450] [Reference Citation Analysis]
201 Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Ann Surg Oncol 2014;21:575-82. [PMID: 24201746 DOI: 10.1245/s10434-013-3343-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
202 Hosoda K, Niihara M, Harada H, Yamashita K, Hiki N. Robot-assisted minimally invasive esophagectomy for esophageal cancer: Meticulous surgery minimizing postoperative complications. Ann Gastroenterol Surg 2020;4:608-17. [PMID: 33319150 DOI: 10.1002/ags3.12390] [Reference Citation Analysis]
203 Doosti-Irani A, Holakouie-Naieni K, Rahimi-Foroushani A, Mansournia MA, Haddad P. A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival. Crit Rev Oncol Hematol 2018;127:80-90. [PMID: 29891115 DOI: 10.1016/j.critrevonc.2018.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
204 Taniyama Y, Sakurai T, Hikage M, Okamoto H, Sato C, Takaya K, Unno M, Kamei T. How does presurgical chemotherapy influence the efficiency of treatment for esophageal cancer recurrence after curative esophagectomy? Thorac Cancer 2019;10:769-74. [PMID: 30756477 DOI: 10.1111/1759-7714.12996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Zheng Y, Li Y, Liu X, Sun H, Wang Z, Zhang R. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) 2015;94:e1102. [PMID: 26166100 DOI: 10.1097/MD.0000000000001102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
206 Park SY, Hong MH, Kim HR, Lee CG, Cho JH, Cho BC, Kim DJ. The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. J Thorac Dis 2020;12:6426-34. [PMID: 33282345 DOI: 10.21037/jtd-20-1088] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
207 Okada N, Fujii S, Fujita T, Kanamori J, Kojima T, Hayashi R, Daiko H. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy. Surgery 2016;159:441-50. [DOI: 10.1016/j.surg.2015.06.044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
208 Ojima T, Iwahashi M, Nakamori M, Nakamura M, Katsuda M, Iida T, Hayata K, Yamaue H. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today 2014;44:839-47. [DOI: 10.1007/s00595-013-0616-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
209 Matsuda S, Takeuchi H, Kawakubo H, Kitagawa Y. Three-field lymph node dissection in esophageal cancer surgery. J Thorac Dis 2017;9:S731-40. [PMID: 28815069 DOI: 10.21037/jtd.2017.03.171] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
210 Yoshida N, Watanabe M, Baba Y, Iwagami S, Ishimoto T, Iwatsuki M, Sakamoto Y, Miyamoto Y, Ozaki N, Baba H. Risk factors for pulmonary complications after esophagectomy for esophageal cancer. Surg Today 2014;44:526-32. [DOI: 10.1007/s00595-013-0577-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 7.8] [Reference Citation Analysis]
211 Tang H, Jiang D, Zhang S, Zeng Z, Tan L, Hou Y, Wang Q, Wang H, Zhu J, Shen Y, Yin J, Ge D; Zhongshan NCRT-EC working group. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2020:S0022-5223(20)32634-9. [PMID: 33268125 DOI: 10.1016/j.jtcvs.2020.09.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
212 Aoyama J, Kawakubo H, Mayanagi S, Fukuda K, Irino T, Nakamura R, Wada N, Suzuki T, Kameyama K, Kitagawa Y. Discrepancy Between the Clinical and Final Pathological Findings of Lymph Node Metastasis in Superficial Esophageal Cancer. Ann Surg Oncol. 2019;26:2874-2881. [PMID: 31209674 DOI: 10.1245/s10434-019-07498-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
213 Farokhi P, Sadeghi A, Moghaddas A, Heidarpour M, Dinari S. Primary Squamous Cell Carcinoma, a Rare Pathological Report of Pancreatic Cancer. Caspian J Intern Med 2021;12:S407-12. [PMID: 34760094 DOI: 10.22088/cjim.12.0.407] [Reference Citation Analysis]
214 Lam KO, Chan WWL, So TH, Kwong DLW. Systemic Therapy for Esophageal Squamous Cell Carcinoma. Methods Mol Biol 2020;2129:321-33. [PMID: 32056188 DOI: 10.1007/978-1-0716-0377-2_24] [Reference Citation Analysis]
215 Yang Z, Ni W, Cui C, Qi W, Piao L, Xuan Y. Identification of LETM1 as a marker of cancer stem-like cells and predictor of poor prognosis in esophageal squamous cell carcinoma. Human Pathology 2018;81:148-56. [DOI: 10.1016/j.humpath.2018.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
216 Yamasaki M, Miyata H, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Perioperative therapy for esophageal cancer. Gen Thorac Cardiovasc Surg 2014;62:531-40. [DOI: 10.1007/s11748-014-0458-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
217 Deng X, Zhao J, Qu L, Duan Z, Fu R, Zhu C, Fan D. Ginsenoside Rh4 suppresses aerobic glycolysis and the expression of PD-L1 via targeting AKT in esophageal cancer. Biochem Pharmacol 2020;178:114038. [PMID: 32422139 DOI: 10.1016/j.bcp.2020.114038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
218 Shafaee A, Dastyar DZ, Islamian JP, Hatamian M. Inhibition of tumor energy pathways for targeted esophagus cancer therapy. Metabolism 2015;64:1193-8. [PMID: 26271140 DOI: 10.1016/j.metabol.2015.07.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
219 Kurahashi Y, Ishida Y, Kumamoto T, Nakanishi Y, Hojo Y, Igeta M, Takemura M, Shinohara H. Anastomosis behind the sternoclavicular joint is associated with increased incidence of anastomotic stenosis in retrosternal reconstruction with a gastric conduit after esophagectomy. Dis Esophagus 2021;34:doaa089. [PMID: 32995867 DOI: 10.1093/dote/doaa089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Pasquer A, Gronnier C, Renaud F, Duhamel A, Théreaux J, Carrere N, Gagniere J, Meunier B, Collet D, Mariette C. Impact of Adjuvant Chemotherapy on Patients with Lymph Node-Positive Esophageal Cancer who are primarily Treated with Surgery. Ann Surg Oncol 2015;22 Suppl 3:S1340-9. [PMID: 26065869 DOI: 10.1245/s10434-015-4658-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
221 Matsuda S, Kawakubo H, Takeuchi H, Hayashi M, Mayanagi S, Takemura R, Irino T, Fukuda K, Nakamura R, Wada N, Kitagawa Y. Minimally invasive oesophagectomy with extended lymph node dissection and thoracic duct resection for early-stage oesophageal squamous cell carcinoma. Br J Surg 2020;107:705-11. [PMID: 32077101 DOI: 10.1002/bjs.11487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
222 Urakawa S, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Mori M, Doki Y. Lymph Node Response to Neoadjuvant Chemotherapy as an Independent Prognostic Factor in Metastatic Esophageal Cancer. Ann Surg 2021;273:1141-9. [PMID: 31274656 DOI: 10.1097/SLA.0000000000003445] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
223 Fujihata S, Ogawa R, Nakaya S, Hayakawa S, Okubo T, Sagawa H, Tanaka T, Takahashi H, Matsuo Y, Takiguchi S. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer. Esophagus 2021;18:258-66. [PMID: 32889673 DOI: 10.1007/s10388-020-00774-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
224 Akiyama Y, Iwaya T, Endo F, Shioi Y, Chiba T, Takahara T, Otsuka K, Nitta H, Koeda K, Mizuno M, Kimura Y, Sasaki A. Stability of cervical esophagogastrostomy via hand-sewn anastomosis after esophagectomy for esophageal cancer. Dis Esophagus 2017;30:1-7. [PMID: 28375439 DOI: 10.1093/dote/dow007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
225 Katsurahara K, Shiozaki A, Fujiwara H, Konishi H, Kudou M, Shoda K, Arita T, Kosuga T, Morimura R, Murayama Y, Kuriu Y, Ikoma H, Kubota T, Nakanishi M, Okamoto K, Otsuji E. Clinical significance of the distance between the cricoid cartilage and upper edge of the tumor using PET-CT in cervical esophageal cancer. Oncol Lett 2020;20:40. [PMID: 32788935 DOI: 10.3892/ol.2020.11901] [Reference Citation Analysis]
226 Wang Q, Peng L, Li T, Dai W, Jiang Y, Xie T, Fang Q, Wang Y, Wu L, Cao B, Han Y, Lang J. Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2020;27:1488-95. [PMID: 31974708 DOI: 10.1245/s10434-019-08112-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
227 Ku GY. Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. Surgical Oncology Clinics of North America 2017;26:241-56. [DOI: 10.1016/j.soc.2016.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
228 Okadome K, Baba Y, Yasuda-Yoshihara N, Nomoto D, Yagi T, Toihata T, Ogawa K, Sawayama H, Ishimoto T, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Watanabe M, Komohara Y, Baba H. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. Cancer Sci 2021. [PMID: 34773342 DOI: 10.1111/cas.15198] [Reference Citation Analysis]
229 Nambara M, Miki Y, Tamura T, Yoshii M, Toyokawa T, Tanaka H, Lee S, Muguruma K, Shibata T, Ohira M. The Optimal Definition of Sarcopenia for Predicting Postoperative Pneumonia after Esophagectomy in Patients with Esophageal Cancer. World J Surg 2021;45:3108-18. [PMID: 34189621 DOI: 10.1007/s00268-021-06223-z] [Reference Citation Analysis]
230 Makino T, Yamasaki M, Tanaka K, Masuike Y, Tatsumi M, Motoori M, Kimura Y, Hatazawa J, Mori M, Doki Y. Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer. Ann Surg 2019;270:1090-5. [PMID: 29727327 DOI: 10.1097/SLA.0000000000002808] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
231 Shimoji H, Karimata H, Nagahama M, Nishimaki T. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg 2013;37:2180-8. [PMID: 23649529 DOI: 10.1007/s00268-013-2074-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
232 Nomura M, Oze I, Kodaira T, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Tachibana H, Uemura N, Tajika M, Niwa Y, Muto M, Muro K. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. Int J Clin Oncol 2016;21:890-8. [PMID: 26980212 DOI: 10.1007/s10147-016-0963-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
233 Zhou C, Fan N, Liu F, Fang N, Plum PS, Thieme R, Gockel I, Gromnitza S, Hillmer AM, Chon SH, Schlösser HA, Bruns CJ, Zhao Y. Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer. Cells 2020;9:E1481. [PMID: 32560537 DOI: 10.3390/cells9061481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
234 Tu CC, Hsu PK. Current choices and prospects in management of postoperative esophageal cancer patients. Asian J Surg 2019;42:81-4. [PMID: 30121147 DOI: 10.1016/j.asjsur.2018.06.009] [Reference Citation Analysis]
235 Kano K, Aoyama T, Yoshikawa T, Maezawa Y, Nakajima T, Hayashi T, Yamada T, Sato T, Oshima T, Rino Y, Masuda M, Cho H, Ogata T. The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer. Ann Surg Oncol 2018;25:2034-43. [PMID: 29748890 DOI: 10.1245/s10434-018-6504-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
236 Kato T, Oshikiri T, Goto H, Urakawa N, Hasegawa H, Kanaji S, Yamashita K, Matsuda T, Nakamura T, Suzuki S, Kakeji Y. Preoperative neutrophil-to-lymphocyte ratio predicts the prognosis of esophageal squamous cell cancer patients undergoing minimally invasive esophagectomy after neoadjuvant chemotherapy. J Surg Oncol 2021;124:1022-30. [PMID: 34460103 DOI: 10.1002/jso.26611] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Hou S, Pan Z, Hao X, Hang Q, Ding Y. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. Cancers (Basel) 2021;13:5162. [PMID: 34680311 DOI: 10.3390/cancers13205162] [Reference Citation Analysis]
238 Arakawa Y, Tamura M, Sakuyama T, Aiba K, Eto S, Yuda M, Tanaka Y, Matsumoto A, Nishikawa K. Early measurement of urinary N-acetyl-β-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy. Journal of Infection and Chemotherapy 2015;21:502-6. [DOI: 10.1016/j.jiac.2015.03.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
239 Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, Li SH. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy. Sci Rep 2017;7:41785. [PMID: 28134308 DOI: 10.1038/srep41785] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
240 Shuto K, Kono T, Shiratori T, Akutsu Y, Uesato M, Mori M, Narushima K, Imanishi S, Nabeya Y, Yanagawa N, Okazumi S, Koda K, Matsubara H. Diagnostic performance of diffusion-weighted magnetic resonance imaging in assessing lymph node metastasis of esophageal cancer compared with PET. Esophagus 2020;17:239-49. [PMID: 31820208 DOI: 10.1007/s10388-019-00704-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
241 Noreen A, Nazli Z, Akram J, Rasul I, Mansha A, Yaqoob N, Iqbal R, Tabasum S, Zuber M, Zia KM. Pectins functionalized biomaterials; a new viable approach for biomedical applications: A review. International Journal of Biological Macromolecules 2017;101:254-72. [DOI: 10.1016/j.ijbiomac.2017.03.029] [Cited by in Crossref: 112] [Cited by in F6Publishing: 77] [Article Influence: 22.4] [Reference Citation Analysis]
242 Knab LM, Belotte J, Munshi HG, Bentrem DJ. Comparative Effectiveness in Esophagogastric Cancer. In: Bilimoria KY, Minami CA, Mahvi DM, editors. Comparative Effectiveness in Surgical Oncology. Cham: Springer International Publishing; 2015. pp. 121-42. [DOI: 10.1007/978-3-319-12553-4_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Maeda Y, Takeuchi H, Matsuda S, Okamura A, Fukuda K, Miyasho T, Nakamura R, Suda K, Wada N, Kawakubo H, Kitagawa Y. Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer. Esophagus 2020;17:279-88. [PMID: 31845119 DOI: 10.1007/s10388-019-00708-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
244 Li Q, Wu SG, Gao JM, Xu JJ, Hu LY, Xu T. Impact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes. J Radiat Res. 2013;54:307-314. [PMID: 23124992 DOI: 10.1093/jrr/rrs096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
245 Kam AE, Pappas SG, Masood A. Postoperative Chemotherapy for Thoracic Pathological T3N0M0 Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2020;27:1314-5. [PMID: 31848823 DOI: 10.1245/s10434-019-08140-x] [Reference Citation Analysis]
246 Kadota T, Abe S, Yoda Y, Yoshinaga S, Oda I, Kojima T, Kato K, Daiko H, Yano T. Clinical outcomes according to the modified endoscopic criteria for neoadjuvant chemotherapy in resectable esophageal squamous cell carcinoma. Dig Endosc 2020;32:337-45. [PMID: 31295769 DOI: 10.1111/den.13483] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
247 Toh Y, Morita M, Yamamoto M, Nakashima Y, Sugiyama M, Uehara H, Fujimoto Y, Shin Y, Shiokawa K, Ohnishi E, Shimagaki T, Mano Y, Sugimachi K. Health-related quality of life after esophagectomy in patients with esophageal cancer. Esophagus 2021. [PMID: 34467435 DOI: 10.1007/s10388-021-00874-6] [Reference Citation Analysis]
248 Yoshida N, Baba Y, Baba H. Preoperative malnutrition and prognosis after neoadjuvant chemotherapy followed by subsequent esophagectomy. J Thorac Dis 2017;9:3437-9. [PMID: 29268308 DOI: 10.21037/jtd.2017.09.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
249 Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara H, Tanaka Y, Saito Y, Nagashima K, Igaki H. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Int J Clin Oncol 2019;24:60-7. [DOI: 10.1007/s10147-018-1336-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
250 Kitagawa K, Okada H, Miyazaki S, Funakoshi Y, Sanada Y, Chayahara N, Mayahara H, Fujii M. Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy: A retrospective analysis. Cancer Med 2021;10:7525-33. [PMID: 34514723 DOI: 10.1002/cam4.4269] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
251 Fujita H. Ways and tradition of Japan in esophageal surgery for cancer. Gen Thorac Cardiovasc Surg 2020;68:1187-92. [DOI: 10.1007/s11748-020-01369-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
252 Haneda R, Booka E, Ishii K, Kikuchi H, Hiramatsu Y, Kamiya K, Ogawa H, Yasui H, Takeuchi H, Tsubosa Y. Evaluation of Definitive Chemoradiotherapy Versus Radical Esophagectomy in Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma. World J Surg 2021;45:1835-44. [PMID: 33620541 DOI: 10.1007/s00268-021-06016-4] [Reference Citation Analysis]
253 Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, Yanagimoto H, Kurata M, Fukumoto T, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS). Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer 2019;19:252. [PMID: 30898101 DOI: 10.1186/s12885-019-5460-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
254 Takebayashi K, Tsubosa Y, Matsuda S, Kawamorita K, Niihara M, Tsushima T, Yokota T, Sato H, Onozawa Y, Ogawa H, Kamijo T, Onitsuka T, Nakagawa M, Yasui H. Comparison of curative surgery and definitive chemoradiotherapy as initial treatment for patients with cervical esophageal cancer. Dis Esophagus 2017;30:1-5. [PMID: 27859977 DOI: 10.1111/dote.12502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
255 Miller JA, Groman A, Yendamuri S, Hennon M. Radiation With Neoadjuvant Chemotherapy Does Not Improve Outcomes in Esophageal Squamous Cell Cancer. J Surg Res 2019;236:259-65. [PMID: 30694764 DOI: 10.1016/j.jss.2018.11.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
256 Sawayama H, Ogata Y, Ishimoto T, Mima K, Hiyoshi Y, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Baba H. Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer. Cancer Sci 2019;110:1705-14. [PMID: 30861255 DOI: 10.1111/cas.13995] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
257 Xiao X, Hong HG, Zeng X, Yang YS, Luan SY, Li Y, Chen LQ, Yuan Y. The Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Esophageal Cancer Patients: A Systematic Review and Meta-Analysis. World J Surg 2020;44:4161-74. [PMID: 32761259 DOI: 10.1007/s00268-020-05721-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Sadrizadeh A, Bagheri R, Soltani E, Anvari K, Toussi MS, Moadikhah S. The Comparison of the Advantages of Neoadjuvant Chemoradiotherapy versus Postoperative Chemoradiotherapy: Outcomes in Esophageal Cancer Patients. J Gastrointest Cancer 2018;49:50-6. [PMID: 28025816 DOI: 10.1007/s12029-016-9899-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
259 Sugawara K, Yamashita H, Uemura Y, Mitsui T, Yagi K, Nishida M, Aikou S, Mori K, Nomura S, Seto Y. Numeric pathologic lymph node classification shows prognostic superiority to topographic pN classification in esophageal squamous cell carcinoma. Surgery 2017;162:846-56. [PMID: 28739092 DOI: 10.1016/j.surg.2017.06.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
260 Yoshida N, Yamamoto H, Baba H, Miyata H, Watanabe M, Toh Y, Matsubara H, Kakeji Y, Seto Y. Can Minimally Invasive Esophagectomy Replace Open Esophagectomy for Esophageal Cancer? Latest Analysis of 24,233 Esophagectomies From the Japanese National Clinical Database. Annals of Surgery 2020;272:118-24. [DOI: 10.1097/sla.0000000000003222] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 10.7] [Reference Citation Analysis]
261 Suzuki T, Yajima S, Ishioka N, Nanami T, Oshima Y, Washizawa N, Funahashi K, Otsuka S, Nemoto T, Shimada H. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma. Esophagus 2018;15:294-300. [PMID: 29959634 DOI: 10.1007/s10388-018-0629-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
262 Kataoka A, Yamada K, Hagiwara T, Terayama M, Sugimoto T, Nohara K, Igari T, Yokoi C, Kawamura YI. Expression Status of Serine Protease 27: A Prognostic Marker for Esophageal Squamous Cell Carcinoma Treated with Preoperative Chemotherapy/Chemoradiotherapy. Ann Surg Oncol 2021;28:5373-81. [PMID: 33452606 DOI: 10.1245/s10434-020-09550-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Hara H, Mizusawa J, Hironaka S, Kato K, Daiko H, Abe T, Nakamura K, Ando N, Kitagawa Y. Influence of preoperative chemotherapy-induced leukopenia on survival in patients with esophageal squamous cell carcinoma: exploratory analysis of JCOG9907. Esophagus 2021;18:41-8. [PMID: 32514753 DOI: 10.1007/s10388-020-00752-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
264 Roy AC, Shapiro J, Burge M, Karapetis CS, Pavlakis N, Segelov E, Chau I, Lordick F, Chen LT, Barbour A, Tebbutt N, Price T. Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2020;20:305-24. [PMID: 32202178 DOI: 10.1080/14737140.2020.1746185] [Reference Citation Analysis]
265 Ohkura Y, Ueno M, Iizuka T, Haruta S, Tanaka T, Udagawa H. Factors Predicting Effectiveness of Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma. Medicine (Baltimore) 2016;95:e3365. [PMID: 27082598 DOI: 10.1097/MD.0000000000003365] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
266 Hikage M, Taniyama Y, Sakurai T, Sato C, Takaya K, Okamoto H, Konno T, Ujiie N, Naitoh T, Unno M, Kamei T. The Influence of the Perioperative Nutritional Status on the Survival Outcomes for Esophageal Cancer Patients with Neoadjuvant Chemotherapy. Ann Surg Oncol 2019;26:4744-53. [PMID: 31440925 DOI: 10.1245/s10434-019-07742-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
267 Yamagata Y, Saito K, Hirano K, Oya M. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus. World J Surg Oncol 2020;18:252. [PMID: 32962718 DOI: 10.1186/s12957-020-02023-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
268 Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res 2020;9:F1000 Faculty Rev-1189. [PMID: 33042518 DOI: 10.12688/f1000research.22926.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Okada N, Daiko H, Kanamori J, Sato A, Horikiri Y, Sato T, Fujiwara H, Tomioka T, Fujita T, Kojima T, Fujii S. Impact of pathologically assessing extranodal extension in the thoracic field on the prognosis of esophageal squamous cell carcinoma. Surgery 2019;165:1203-10. [DOI: 10.1016/j.surg.2018.12.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
270 Maeda O, Ando Y. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World J Gastrointest Oncol 2019; 11(7): 518-526 [PMID: 31367271 DOI: 10.4251/wjgo.v11.i7.518] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
271 Chen H, Wu Z, Chen J, Lin X, Zheng C, Fan Y, Zhang Z, Yao X, Wu J, Xu L, Li E. Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 cases. Med Oncol 2015;32:417. [PMID: 25479943 DOI: 10.1007/s12032-014-0417-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
272 Miyata H, Yamasaki M, Makino T, Tatsumi M, Miyazaki Y, Takahashi T, Kurokawa Y, Takiguchi S, Mori M, Doki Y. Impact of number of [(18)F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. Br J Surg 2016;103:97-104. [PMID: 26506079 DOI: 10.1002/bjs.9965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
273 Tanaka E, Okabe H, Tsunoda S, Obama K, Kan T, Kadokawa Y, Akagami M, Sakai Y. Feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy. Asian J Endosc Surg 2012;5:111-7. [PMID: 22776501 DOI: 10.1111/j.1758-5910.2012.00131.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
274 Chen D, Wang W, Mo J, Ren Q, Miao H, Chen Y, Wen Z. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments. BMC Cancer 2021;21:145. [PMID: 33563244 DOI: 10.1186/s12885-021-07867-9] [Reference Citation Analysis]
275 Hirose Y, Kaida H, Kawahara A, Matono S, Tanaka T, Kurata S, Kage M, Ishibashi M, Abe T. Molecular biological correlation of fluorine-18 fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Nucl Med Commun 2016;37:1053-61. [PMID: 27218430 DOI: 10.1097/MNM.0000000000000550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
276 Sugimura K, Yamasaki M, Yasuda T, Yano M, Hirao M, Fujitani K, Kimura Y, Miyata H, Motoori M, Takeno A, Shiraishi O, Makino T, Kii T, Tanaka K, Satoh T, Mori M, Doki Y. Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003). Ann Gastroenterol Surg 2021;5:75-82. [PMID: 33532683 DOI: 10.1002/ags3.12388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
277 Mulligan CR Jr. Multidisciplinary management of esophageal cancer. Surg Oncol Clin N Am 2013;22:217-46. [PMID: 23453332 DOI: 10.1016/j.soc.2012.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
278 Mori T, Kumagai K, Nasu K, Yoshizawa T, Kuwano K, Hamada Y, Kanazawa H, Suzuki R. Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy. Int J Mol Sci 2021;22:1098. [PMID: 33499345 DOI: 10.3390/ijms22031098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Kitagawa H, Namikawa T, Iwabu J, Uemura S, Munekage M, Yokota K, Kobayashi M, Hanazaki K. Bowel obstruction associated with a feeding jejunostomy and its association to weight loss after thoracoscopic esophagectomy. BMC Gastroenterol. 2019;19:104. [PMID: 31238878 DOI: 10.1186/s12876-019-1029-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
280 Cox SJ, O'Cathail SM, Coles B, Crosby T, Mukherjee S. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Curr Oncol Rep 2017;19:7. [PMID: 28213876 DOI: 10.1007/s11912-017-0559-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
281 Shiozaki A, Fujiwara H, Murayama Y, Komatsu S, Kuriu Y, Ikoma H, Nakanishi M, Ichikawa D, Okamoto K, Ochiai T. Perioperative outcomes of esophagectomy preceded by the laparoscopic transhiatal approach for esophageal cancer. Dis Esophagus. 2014;27:470-478. [PMID: 23088181 DOI: 10.1111/j.1442-2050.2012.01439.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
282 Satomura H, Nakajima M, Sasaki K, Yamaguchi S, Domeki Y, Takahashi M, Muroi H, Kubo T, Kikuchi M, Otomo H, Ihara K, Kato H. Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma. Int Surg 2015;100:1153-8. [PMID: 26414837 DOI: 10.9738/INTSURG-D-14-00233.1] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
283 Okumura T, Shimada Y, Hojo S, Sekine S, Hirano K, Moriyama M, Miwa S, Nagata T, Tsukada K. Perforation of intramural gastric metastasis during preoperative chemotherapy in a patient with thoracic esophageal squamous cell carcinoma. Int J Surg Case Rep 2015;17:23-7. [PMID: 26519812 DOI: 10.1016/j.ijscr.2015.10.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
284 Koterazawa Y, Oshikiri T, Takiguchi G, Hasegawa H, Yamamoto M, Kanaji S, Yamashita K, Matsuda T, Nakamura T, Fujino Y, Tominaga M, Suzuki S, Kakeji Y. Prophylactic Cervical Lymph Node Dissection in Thoracoscopic Esophagectomy for Esophageal Cancer Increases Postoperative Complications and Does Not Improve Survival. Ann Surg Oncol 2019;26:2899-904. [DOI: 10.1245/s10434-019-07499-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
285 Mahawongkajit P, Tomtitchong P. Expression of miRNA in 5-FU resistant esophageal cancer. Mol Clin Oncol 2020;13:221-7. [PMID: 32714549 DOI: 10.3892/mco.2020.2070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
286 Ogawa K, Ishikawa H, Hisakura K, Hiroshima Y, Moriwaki T, Yamada T, Yamamoto Y, Akashi Y, Owada Y, Ohara Y, Enomoto T, Furuya K, Doi M, Shimomura O, Takahashi K, Hashimoto S, Sakurai H, Oda T. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma. Int J Clin Oncol 2021. [PMID: 34241725 DOI: 10.1007/s10147-021-01981-1] [Reference Citation Analysis]
287 Holakouie-Naieni K, Mansournia MA, Doosti-Irani A, Rahimi-Foroushani A, Haddad P. Treatment-related complications in patients with esophageal cancer: A systematic review and network meta-analysis. Surgeon 2021;19:37-48. [PMID: 32209308 DOI: 10.1016/j.surge.2020.01.010] [Reference Citation Analysis]
288 Shishido Y, Matsunaga T, Sawata S, Makinoya M, Miyauchi W, Miyatani K, Uejima C, Morimoto M, Murakami Y, Hanaki T, Kihara K, Yamamoto M, Tokuyasu N, Takano S, Sakamoto T, Saito H, Hasegawa T, Fujiwara Y. Platelet-to-Lymphocyte Ratio Multiplied by the Cytokeratin-19 Fragment Level as a Predictor of Pathological Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. Yonago Acta Med 2021;64:249-59. [PMID: 34434065 DOI: 10.33160/yam.2021.08.003] [Reference Citation Analysis]
289 Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, Osuga T, Hirakawa M, Miyanishi K, Sagawa T, Fujikawa K, Ohi M, Okagawa Y, Tsuji Y, Hirayama M, Ito T, Nobuoka T, Takemasa I, Kobune M, Kato J. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study. Cancer Sci. 2018;109:3554-3563. [PMID: 30137686 DOI: 10.1111/cas.13772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
290 Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14(24): 3773-3780 [PMID: 18609699 DOI: 10.3748/wjg.14.3773] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
291 Stahl M, Ruhstaller T. [Combined modality treatment of oesophageal cancer]. Internist (Berl) 2014;55:7-8, 10-4. [PMID: 24154497 DOI: 10.1007/s00108-013-3315-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
292 Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, Imamura Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today 2020;50:12-20. [PMID: 31535225 DOI: 10.1007/s00595-019-01878-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
293 Oh D, Kim JH. The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:160-7. [PMID: 32793446 DOI: 10.5090/kjtcs.2020.53.4.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
294 Imanishi S, Shuto K, Aoyagi T, Kono T, Saito H, Matsubara H. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma. Dig Surg. 2013;30:240-248. [PMID: 23880636 DOI: 10.1159/000351435] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
295 Qin RQ, Wen YS, Wang WP, Xi KX, Yu XY, Zhang LJ. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis. Med Oncol. 2016;33:31. [PMID: 26922662 DOI: 10.1007/s12032-016-0746-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
296 Yamazato Y, Shiozaki A, Ichikawa D, Kosuga T, Shoda K, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Konishi E, Marunaka Y, Otsuji E. Aquaporin 1 suppresses apoptosis and affects prognosis in esophageal squamous cell carcinoma. Oncotarget 2018;9:29957-74. [PMID: 30042826 DOI: 10.18632/oncotarget.25722] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
297 Feng JF, Wang L, Yang X, Jiang YH. Prognostic value of lactate dehydrogenase to albumin ratio (LAR) in patients with resectable esophageal squamous cell carcinoma. Cancer Manag Res 2019;11:7243-51. [PMID: 31447584 DOI: 10.2147/CMAR.S208320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
298 Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, Moriya S, Tachibana H, Nakamura N, Kojima T, Akimoto T. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2018;13:23. [PMID: 29426342 DOI: 10.1186/s13014-018-0966-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
299 Tsutsui M, Kawakubo H, Hayashida T, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, Takeuchi H, Kitagawa Y. Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma. Int J Oncol 2015;47:867-74. [PMID: 26202837 DOI: 10.3892/ijo.2015.3085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
300 Matsuda S, Kawakubo H, Takeuchi H, Mayanagi S, Irino T, Fukuda K, Nakamura R, Wada N, Kitagawa Y. Prognostic impact of thoracic duct lymph node metastasis in esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2021;5:321-30. [PMID: 34095722 DOI: 10.1002/ags3.12432] [Reference Citation Analysis]
301 Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, Yamashita K, Saito T, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Mori M, Doki Y, Wada H. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci 2020;111:1103-12. [PMID: 31981293 DOI: 10.1111/cas.14328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
302 Okada G, Matsumoto Y, Nakamura Y, Hayashi F, Kato K, Momoki C, Yasui Y, Habu D, Edagawa E, Matsuda Y, Kishida S, Lee S, Osugi H. Nutritional changes and factors contributing to postoperative weight recovery after esophagectomy. Esophagus 2017;14:343-50. [DOI: 10.1007/s10388-017-0584-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
303 Takada A, Nakamura T, Takayama K, Makita C, Suzuki M, Azami Y, Kato T, Tsukiyama I, Hareyama M, Kikuchi Y, Daimon T, Toyomasu Y, Ii N, Nomoto Y, Sakuma H, Fuwa N. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer. Cancer Med 2016;5:506-15. [PMID: 26806272 DOI: 10.1002/cam4.607] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
304 Ohnuma H, Sato Y, Hirakawa M, Okagawa Y, Osuga T, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Sagawa T, Hori M, Someya M, Nakata K, Sakata K, Takayama T, Kato J. A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. Int J Radiat Oncol Biol Phys 2015;93:382-90. [PMID: 26232855 DOI: 10.1016/j.ijrobp.2015.05.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
305 Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L, Chen KN. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Surg 2021;156:444-51. [PMID: 33729467 DOI: 10.1001/jamasurg.2021.0133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
306 Wakatsuki K, Matsumoto S, Migita K, Ito M, Kunishige T, Nakade H, Nakatani M, Kitano M, Takano M, Obayashi C, Sho M. Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy. Surgery 2017;162:823-35. [DOI: 10.1016/j.surg.2017.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
307 Qi WX, Chen C, Zhao S, Chen J. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of locally advanced esophageal cancer: a population-based analysis. Int J Clin Oncol 2021. [PMID: 34731352 DOI: 10.1007/s10147-021-02056-x] [Reference Citation Analysis]
308 Watanabe M. Recent Topics and Perspectives on Esophageal Cancer in Japan. JMA J 2018;1:30-9. [PMID: 33748520 DOI: 10.31662/jmaj.2018-0002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
309 Tang H, Zheng H, Tan L, Shen Y, Wang H, Lin M, Wang Q. Neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy: is it a superior approach for locally advanced resectable esophageal squamous cell carcinoma? J Thorac Dis. 2018;10:963-972. [PMID: 29607169 DOI: 10.21037/jtd.2017.12.108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
310 Motoori M, Yano M, Yasuda T, Miyata H, Peng Y, Yamasaki M, Shiraishi O, Tanaka K, Ishikawa O, Shiozaki H, Doki Y. Early response to neoadjuvant chemotherapy in advanced esophageal cancer evaluated by computed tomography predicts the utility of a second cycle of chemotherapy. Mol Clin Oncol 2013;1:521-6. [PMID: 24649204 DOI: 10.3892/mco.2013.89] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
311 Kitagawa Y, Ando N, Nakamura K, Shibata T, Fukuda H. The Role of Adjuvant Chemotherapy for Localized Squamous Cell Esophageal Cancer: Current Japanese Standard and the Unending Role of the Drawing Board. Ann Surg Oncol 2012;19:1425-7. [DOI: 10.1245/s10434-012-2250-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
312 Song HY, Deng XH, Hou XF, Yuan GY, Zhu ZD, Ren MX. Effect of ECRG2 in combination with cisplatin on the proliferation and apoptosis of EC9706 cells. Exp Ther Med 2014;8:1484-8. [PMID: 25289046 DOI: 10.3892/etm.2014.1972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
313 Sonohara F, Gao F, Iwata N, Kanda M, Koike M, Takahashi N, Yamada Y, Kodera Y, Wang X, Goel A. Genome-wide Discovery of a Novel Gene-expression Signature for the Identification of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma. Ann Surg 2019;269:879-86. [PMID: 29240008 DOI: 10.1097/SLA.0000000000002622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
314 Cools-lartigue J, Ferri L. Should Multidisciplinary Treatment Differ for Esophageal Adenocarcinoma Versus Esophageal Squamous Cell Cancer? Ann Surg Oncol 2019;26:1014-27. [DOI: 10.1245/s10434-019-07162-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
316 Takiguchi S, Murakami K, Yanagimoto Y, Takata A, Miyazaki Y, Mori M, Doki Y. Clinical application of ghrelin in the field of surgery. Surg Today 2015;45:801-7. [PMID: 25366350 DOI: 10.1007/s00595-014-1040-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
317 Kanda M, Koike M, Shimizu D, Tanaka C, Hattori N, Hayashi M, Yamada S, Omae K, Kodera Y. Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Ann Surg Oncol 2020;27:3195-205. [PMID: 32246314 DOI: 10.1245/s10434-020-08433-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
318 Matsuda S, Takeuchi H, Kawakubo H, Shimada A, Fukuda K, Nakamura R, Takahashi T, Wada N, Kameyama K, Kitagawa Y. Clinical outcome of transthoracic esophagectomy with thoracic duct resection: Number of dissected lymph node and distribution of lymph node metastasis around the thoracic duct. Medicine (Baltimore) 2016;95:e3839. [PMID: 27310961 DOI: 10.1097/MD.0000000000003839] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 6.4] [Reference Citation Analysis]
319 Yamashita K, Watanabe M, Mine S, Fukudome I, Okamura A, Yuda M, Hayami M, Imamura Y. The impact of the Charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent. Surg Today. 2018;48:632-639. [PMID: 29383595 DOI: 10.1007/s00595-018-1630-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
320 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma. Thorac Cancer 2020;11:2170-7. [PMID: 32510875 DOI: 10.1111/1759-7714.13524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
321 Nomura H, Hatogai K, Maki Y, Mochizuki N, Tanaka M, Saito S, Daiko H, Kojima T, Kawasaki T. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer 2020;28:1849-54. [DOI: 10.1007/s00520-019-05001-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
322 Otowa Y, Nakamura T, Takiguchi G, Tomono A, Yamamoto M, Kanaji S, Imanishi T, Suzuki S, Tanaka K, Itoh T, Kakeji Y. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer. Diseases of the Esophagus 2016;29:146-51. [DOI: 10.1111/dote.12316] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
323 Iwasaki H, Tanaka T, Miyake S, Yoda Y, Noshiro H. Postoperative hiatal hernia after minimally invasive esophagectomy for esophageal cancer. J Thorac Dis 2020;12:4661-9. [PMID: 33145039 DOI: 10.21037/jtd-20-1335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
324 Lu YX, Chen DL, Wang DS, Chen LZ, Mo HY, Sheng H, Bai L, Wu QN, Yu HE, Xie D, Yun JP, Zeng ZL, Wang F, Ju HQ, Xu RH. Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. Cell Death Dis 2016;7:e2432. [PMID: 27787516 DOI: 10.1038/cddis.2016.330] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
325 Triantafyllou T, Wijnhoven BPL. Current status of esophageal cancer treatment. Chin J Cancer Res 2020;32:271-86. [PMID: 32694894 DOI: 10.21147/j.issn.1000-9604.2020.03.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
326 Sun HB, Xing WQ, Liu XB, Zheng Y, Yang SJ, Wang ZF, Liu SL, Ba YF, Zhang RX, Liu BX, Fan CC, Chen PN, Liang GH, Yu YK, Liu Q, Wang HR, Li HM, Li ZX; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer 2020;20:303. [PMID: 32293362 DOI: 10.1186/s12885-020-06824-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
327 Sasaki K, Uchikado Y, Omoto I, Arigami T, Osako Y, Noda M, Okumura H, Maemura K, Higashi R, Yoshiura T, Natsugoe S. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2019;83:581-7. [DOI: 10.1007/s00280-018-03764-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
328 Akutsu Y, Kono T, Uesato M, Hoshino I, Murakami K, Fujishiro T, Imanishi S, Endo S, Toyozumi T, Matsubara H. Are Additional Trace Elements Necessary in Total Parenteral Nutrition for Patients with Esophageal Cancer Receiving Cisplatin-Based Chemotherapy? Biol Trace Elem Res 2012;150:109-15. [DOI: 10.1007/s12011-012-9513-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
329 Sugita Y, Nakamura T, Sawada R, Takiguchi G, Urakawa N, Hasegawa H, Yamamoto M, Kanaji S, Matsuda Y, Yamashita K, Matsuda T, Oshikiri T, Suzuki S, Kakeji Y. Safety and feasibility of minimally invasive esophagectomy for elderly esophageal cancer patients. Dis Esophagus 2021;34:doaa083. [PMID: 32895704 DOI: 10.1093/dote/doaa083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
331 Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van der Sangen MJC, Rozema T, Ten Kate FJW, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS Study Group. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol 2021;39:1995-2004. [PMID: 33891478 DOI: 10.1200/JCO.20.03614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
332 Kanda M, Koike M, Iwata N, Shimizu D, Tanaka C, Hattori N, Hayashi M, Yamada S, Omae K, Nakayama G, Kodera Y. An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. Oncologist 2020;25:e1650-4. [PMID: 32557987 DOI: 10.1634/theoncologist.2020-0546] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
333 Umezawa R, Jingu K, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Kadoya N, Takeda K, Ariga H, Nemoto K, Yamada S. Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols. BMC Cancer 2015;15:813. [PMID: 26506988 DOI: 10.1186/s12885-015-1836-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
334 Yanagimoto Y, Takiguchi S, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Hosoda H, Kangawa K, Mori M, Doki Y. Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial. Br J Cancer 2016;114:1318-25. [PMID: 27253174 DOI: 10.1038/bjc.2016.160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
335 Ueki S, Fujishima F, Kumagai T, Ishida H, Okamoto H, Takaya K, Sato C, Taniyma Y, Kamei T, Sasano H. GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy. BMC Cancer 2020;20:161. [PMID: 32106831 DOI: 10.1186/s12885-020-6652-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
336 Kato F, Daiko H, Kanamori J, Inamoto Y, Fukuda T, Hayashi K, Tachimori Y, Koyanagi K. Esophagectomy for the patients with squamous cell carcinoma of the esophagus after allogeneic hematopoietic stem cell transplantation. Int J Clin Oncol 2020;25:82-8. [PMID: 31549271 DOI: 10.1007/s10147-019-01549-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
337 Fujisawa R, Iwaya T, Endo F, Idogawa M, Sasaki N, Hiraki H, Tange S, Hirano T, Koizumi Y, Abe M, Takahashi T, Yaegashi M, Akiyama Y, Masuda M, Sasaki A, Takahashi F, Sasaki Y, Tokino T, Nishizuka SS. Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer. Carcinogenesis 2021;42:1239-49. [PMID: 34559206 DOI: 10.1093/carcin/bgab088] [Reference Citation Analysis]
338 Nishimura J, Deguchi S, Tanaka H, Yamakoshi Y, Yoshii M, Tamura T, Toyokawa T, Lee S, Muguruma K, Ohira M. Induction of Immunogenic Cell Death of Esophageal Squamous Cell Carcinoma by 5-Fluorouracil and Cisplatin. In Vivo 2021;35:743-52. [PMID: 33622867 DOI: 10.21873/invivo.12315] [Reference Citation Analysis]
339 Otani T, Ichikawa H, Hanyu T, Ishikawa T, Kano Y, Kanda T, Kosugi SI, Wakai T. Long-Term Trends in Respiratory Function After Esophagectomy for Esophageal Cancer. J Surg Res 2020;245:168-78. [PMID: 31421359 DOI: 10.1016/j.jss.2019.07.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
340 Hiraki Y, Kimura Y, Imano M, Kato H, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Makino T, Motoori M, Yamasaki M, Miyata H, Satou T, Satoh T, Furukawa H, Yano M, Doki Y, Yasuda T. Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma. Surg Today 2021;51:118-26. [PMID: 32596796 DOI: 10.1007/s00595-020-02059-7] [Reference Citation Analysis]
341 Tartaglione MF, Eléxpuru Zabaleta M, Lazzarini R, Piva F, Busilacchi EM, Poloni A, Ledda C, Rapisarda V, Santarelli L, Bracci M. Apoptotic mechanism activated by blue light and cisplatinum in cutaneous squamous cell carcinoma cells. Int J Mol Med 2021;47:48. [PMID: 33576463 DOI: 10.3892/ijmm.2021.4881] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Baba Y, Watanabe M, Yoshida N, Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol 2014; 6(5): 121-128 [PMID: 24834142 DOI: 10.4251/wjgo.v6.i5.121] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
343 Ashok A, Tiwari V, Jiwnani S, Karimundackal G, Pramesh CS. Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research. Ann Gastroenterol Surg 2019;3:592-7. [PMID: 31788647 DOI: 10.1002/ags3.12301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
344 Makino T, Yamasaki M, Miyata H, Tanaka K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Solitary Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma: Surgical Failure or Systemic Disease? Ann Surg Oncol 2016;23:2087-93. [DOI: 10.1245/s10434-015-5086-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
345 Hoshino I, Akutsu Y, Murakami K, Akanuma N, Isozaki Y, Maruyama T, Toyozumi T, Matsumoto Y, Suito H, Takahashi M, Sekino N, Komatsu A, Suzuki T, Matsubara H. Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells. Ann Surg Oncol 2016;23:312-20. [PMID: 25791791 DOI: 10.1245/s10434-015-4488-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
346 Ishikawa T, Kanda T, Kameyama H, Wakai T. Neoadjuvant therapy for gastrointestinal stromal tumor. Transl Gastroenterol Hepatol 2018;3:3. [PMID: 29441368 DOI: 10.21037/tgh.2018.01.01] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
347 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
348 Koga N, Hu Q, Sakai A, Takada K, Nakanishi R, Hisamatsu Y, Ando K, Kimura Y, Oki E, Oda Y, Mori M. Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma. Cancer Sci 2021;112:3018-28. [PMID: 34009732 DOI: 10.1111/cas.14971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
349 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
350 Kitajima T, Kaida S, Lee S, Haruta S, Shinohara H, Ueno M, Suyama K, Oota Y, Fujii T, Udagawa H. Mixed adeno(neuro)endocrine carcinoma arising from the ectopic gastric mucosa of the upper thoracic esophagus. World J Surg Oncol. 2013;11:218. [PMID: 24139488 DOI: 10.1186/1477-7819-11-218] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
351 Kakeji Y, Oshikiri T, Takiguchi G, Kanaji S, Matsuda T, Nakamura T, Suzuki S. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy. Esophagus. 2021;18:25-32. [PMID: 32964312 DOI: 10.1007/s10388-020-00782-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
352 Yokota T, Serizawa M, Hosokawa A, Kusafuka K, Mori K, Sugiyama T, Tsubosa Y, Koh Y. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue. BMC Cancer 2018;18:826. [PMID: 30115035 DOI: 10.1186/s12885-018-4733-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
353 Takeuchi H. Will definitive chemoradiotherapy be a new normal for patients with resectable locally advanced esophageal cancer? Esophagus 2020;17:363-4. [PMID: 32886211 DOI: 10.1007/s10388-020-00780-3] [Reference Citation Analysis]
354 Takeuchi M, Kawakubo H, Mayanagi S, Irino T, Fukuda K, Nakamura R, Wada N, Takeuchi H, Kitagawa Y. Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study. Ann Surg Oncol 2019;26:2081-9. [PMID: 30937664 DOI: 10.1245/s10434-019-07312-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
355 Yaegashi A, Yoshida K, Suzuki N, Shimada I, Tani Y, Saijo Y, Toyama A. A case of severe hepatotoxicity induced by cisplatin and 5-fluorouracil. Int Cancer Conf J 2020;9:24-7. [PMID: 31950013 DOI: 10.1007/s13691-019-00394-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Koterazawa Y, Oshikiri T, Hasegawa H, Yamamoto M, Kanaji S, Yamashita K, Matsuda T, Nakamura T, Suzuki S, Kakeji Y. Routine placement of feeding jejunostomy tube during esophagectomy increases postoperative complications and does not improve postoperative malnutrition. Dis Esophagus 2020;33:doz021. [PMID: 30997494 DOI: 10.1093/dote/doz021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
357 Sugase T, Makino T, Yamasaki M, Tanaka K, Hashimoto T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Mano M, Morii E, Mori M, Doki Y. Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy. Esophagus 2018. [PMID: 29909488 DOI: 10.1007/s10388-018-0626-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
358 Okabe H, Tsunoda S, Sunagawa H, Saji M, Hirai K, Nakau M, Tanaka E, Obama K. A long-term follow-up study of minimally invasive Ivor Lewis esophagectomy with linear stapled anastomosis. Surg Endosc 2021. [PMID: 33837477 DOI: 10.1007/s00464-021-08482-2] [Reference Citation Analysis]
359 Suzuki T, Okamura A, Watanabe M, Mine S, Imamura Y, Asari T, Osumi H, Nakayama I, Ichimura T, Ogura M, Ooki A, Takahari D, Yamaguchi K, Chin K. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2020;27:1510-7. [DOI: 10.1245/s10434-019-08124-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
360 Wakita A, Motoyama S, Sato Y, Nagaki Y, Fujita H, Terata K, Imai K, Minamiya Y. Verification of the Optimal Interval Before Esophagectomy After Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer. Ann Surg Oncol 2021;28:2101-10. [PMID: 33051740 DOI: 10.1245/s10434-020-09206-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
361 Fujishiro T, Shuto K, Hayano K, Satoh A, Kono T, Ohira G, Tohma T, Gunji H, Narushima K, Tochigi T. Preoperative hepatic CT perfusion as an early predictor for the recurrence of esophageal squamous cell carcinoma: initial clinical results. Oncol Rep. 2014;31:1083-1088. [PMID: 24452736 DOI: 10.3892/or.2014.2992] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
362 Matsuda S, Kawakubo H, Tsuji T, Aoyama J, Hirata Y, Takemura R, Mayanagi S, Irino T, Fukuda K, Nakamura R, Takeuchi H, Kitagawa Y. Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021. [PMID: 34812985 DOI: 10.1245/s10434-021-11009-7] [Reference Citation Analysis]
363 Kume M, Yasui H, Yoshikawa Y, Horinouchi M, Higashiguchi K, Kobayashi Y, Kuroda D, Hirano T, Hirai M, Nakamura T. Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. Cancer Chemother Pharmacol 2012;69:1537-44. [DOI: 10.1007/s00280-012-1860-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
364 Kurokawa Y, Shibata T, Ando N, Seki S, Mukaida H, Fukuda H. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol 2013;20:3009-14. [PMID: 23504143 DOI: 10.1245/s10434-013-2946-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
365 Motoi F, Unno M, Takahashi H, Okada T, Wada K, Sho M, Nagano H, Matsumoto I, Satoi S, Murakami Y, Kishiwada M, Honda G, Kinoshita H, Baba H, Hishinuma S, Kitago M, Tajima H, Shinchi H, Takamori H, Kosuge T, Yamaue H, Takada T. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2014;21:148-158. [PMID: 23913634 DOI: 10.1002/jhbp.15] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
366 Baba Y, Saeki H, Nakashima Y, Oki E, Shigaki H, Yoshida N, Watanabe M, Maehara Y, Baba H. Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. Dis Esophagus 2017;30:1-7. [PMID: 27868285 DOI: 10.1111/dote.12521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
367 Tian D, Zhang L, Wang Y, Chen L, Zhang K, Zhou Y, Wen H, Fu M. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes. Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
368 Hayakawa Y, Kobayashi K, Sakamoto N, Matsuoka M, Nozaka T, Misumi Y, Matsumoto T, Miura N, Furumoto Y, Asano T, Horiuchi T, Fujiki K. A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. Clin J Gastroenterol 2020;13:17-21. [PMID: 31352645 DOI: 10.1007/s12328-019-01028-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
369 Sugimura K, Miyata H, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol. 2015;111:752-759. [PMID: 25752960 DOI: 10.1002/jso.23881] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
370 Lyu X, Huang J, Mao Y, Liu Y, Feng Q, Shao K, Gao S, Jiang Y, Wang J, He J. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? J Surg Oncol. 2014;110:864-868. [PMID: 24976079 DOI: 10.1002/jso.23716] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
371 Teshima J, Miyata G, Kamei T, Nakano T, Abe S, Katsura K, Taniyama Y, Sakurai T, Hikage M, Nakamura T, Takaya K, Zuguchi M, Okamoto H, Youhei O, Ohuchi N. Comparison of short-term outcomes between prone and lateral decubitus positions for thoracoscopic esophagectomy. Surg Endosc 2015;29:2756-62. [PMID: 25480621 DOI: 10.1007/s00464-014-4003-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
372 Wakatsuki K, Matsumoto S, Migita K, Ito M, Kunishige T, Nakade H, Nakatani M, Kitano M, Sho M. Preoperative Plasma Fibrinogen is Associated with Lymph Node Metastasis and Predicts Prognosis in Resectable Esophageal Cancer. World J Surg 2017;41:2068-77. [DOI: 10.1007/s00268-017-3991-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
373 Yokota T, Yasuda T, Kato H, Nozaki I, Sato H, Miyata Y, Kuroki Y, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Kitagawa Y. Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. Int J Clin Oncol 2018;23:73-80. [PMID: 28744724 DOI: 10.1007/s10147-017-1168-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
374 Purwar P, Bambarkar S, Jiwnani S, Karimundackal G, Laskar SG, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg 2014;76:494-503. [PMID: 25614726 DOI: 10.1007/s12262-014-1163-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
375 Ma Z, Yuan M, Bao Y, Wang Y, Men Y, Hui Z. Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis. Front Oncol 2021;11:728185. [PMID: 34745950 DOI: 10.3389/fonc.2021.728185] [Reference Citation Analysis]
376 Yamamoto S, Kato K. Pembrolizumab for the treatment of esophageal cancer. Expert Opin Biol Ther 2020;20:1143-50. [PMID: 32620063 DOI: 10.1080/14712598.2020.1792881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
377 Murakami T, Shoji Y, Nishi T, Chang SC, Jachimowicz RD, Hoshimoto S, Ono S, Shiloh Y, Takeuchi H, Kitagawa Y, Hoon DSB, Bustos MA. Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. Mol Oncol 2021;15:1069-87. [PMID: 33605536 DOI: 10.1002/1878-0261.12929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
378 Hironaka S, Komori A, Machida R, Ito Y, Takeuchi H, Ogawa G, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Nozaki I, Ura T, Chin K, Fukuda H, Kitagawa Y. The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus 2020;17:417-24. [PMID: 32342253 DOI: 10.1007/s10388-020-00741-w] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
379 Hayashi Y, Nishida T, Tsujii M, Tsutsui S, Yamamoto K, Isohashi F, Yamasaki M, Miyata H, Kato M, Yamada T. Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma. BMC Cancer. 2014;14:706. [PMID: 25253238 DOI: 10.1186/1471-2407-14-706] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
380 Nomura M, Kato K, Ando N, Ohtsu A, Muro K, Igaki H, Abe T, Takeuchi H, Daiko H, Gotoh M, Kataoka K, Wakabayashi M, Kitagawa Y. Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). Jpn J Clin Oncol 2017;47:480-6. [PMID: 28334858 DOI: 10.1093/jjco/hyx040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
381 Ida S, Watanabe M, Karashima R, Imamura Y, Ishimoto T, Baba Y, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Baba H. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. Ann Surg Oncol. 2014;21:3675-3679. [PMID: 24793436 DOI: 10.1245/s10434-014-3737-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
382 Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36:617-622. [PMID: 22223293 DOI: 10.1007/s00268-011-1411-1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 100] [Article Influence: 9.7] [Reference Citation Analysis]
383 Hatogai K, Fujii S, Kojima T, Daiko H, Kadota T, Fujita T, Yoshino T, Doi T, Takiguchi Y, Ohtsu A. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. J Surg Oncol 2016;113:390-6. [PMID: 27100024 DOI: 10.1002/jso.24151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
384 Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, Imai K, Minamiya Y. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy. BMC Cancer 2021;21:1192. [PMID: 34753448 DOI: 10.1186/s12885-021-08918-x] [Reference Citation Analysis]
385 Kuroda J, Yoshida M, Kitajima M, Yanagisawa A, Matsubara T, Yamaguchi T, Osamura Y, Ohta K, Kubota K, Beck Y, Yamashita Y. Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma. J Gastroenterol Hepatol 2012;27 Suppl 3:88-94. [PMID: 22486878 DOI: 10.1111/j.1440-1746.2012.07078.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
386 Nakajima Y, Kawada K, Tokairin Y, Miyawaki Y, Okada T, Ryotokuji T, Fujiwara N, Saito K, Fujiwara H, Ogo T, Okuda M, Nagai K, Miyake S, Kawano T. Salvage chemoradiotherapy for locally advanced esophageal carcinomas. Dis Esophagus 2015;28:460-7. [PMID: 24720357 DOI: 10.1111/dote.12217] [Reference Citation Analysis]
387 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
388 Noshiro H, Yoda Y, Hiraki M, Kono H, Miyake S, Uchiyama A, Nagai E. Survival outcomes of 220 consecutive patients with three-staged thoracoscopic esophagectomy. Dis Esophagus 2016;29:1090-9. [PMID: 26541471 DOI: 10.1111/dote.12426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
389 Shimada A, Takeuchi H, Fukuda K, Suda K, Nakamura R, Wada N, Kawakubo H, Kitagawa Y. Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin. Esophagus 2018;15:209-16. [PMID: 30225740 DOI: 10.1007/s10388-018-0615-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
390 Takao K, Konishi H, Fujiwara H, Shiozaki A, Shoda K, Kosuga T, Kubota T, Arita T, Morimura R, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Okamoto K, Otsuji E. Clinical Significance of Prognostic Nutritional Index in the Treatment of Esophageal Squamous Cell Carcinoma. In Vivo 2020;34:3451-7. [PMID: 33144453 DOI: 10.21873/invivo.12184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
391 Ilson DH, van Hillegersberg R. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. Gastroenterology 2018;154:437-51. [DOI: 10.1053/j.gastro.2017.09.048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
392 Ye G, Chen Z, Wang L, Hu Z, Bian Y, Yang X, Lu T, Zhan C, Lin Z, Wang Q. Log odds of positive lymph nodes predicts survival in patients treated with neoadjuvant therapy followed by esophagectomy. J Surg Oncol 2020;121:1074-83. [PMID: 32141098 DOI: 10.1002/jso.25888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
393 Mine S, Watanabe M, Kumagai K, Okamura A, Yuda M, Hayami M, Yamashita K, Imamura Y, Ishizuka N. Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction. Dis Esophagus 2019;32:doz002. [PMID: 30791046 DOI: 10.1093/dote/doz002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
394 Hiranyatheb P, Osugi H. Radical lymphadenectomy in esophageal cancer: from the past to the present. Dis Esophagus. 2013;Jun 24; Epub ahead of print. [PMID: 23796327 DOI: 10.1111/dote.12091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
395 Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H. Pyloroplasty may reduce weight loss 1 year after esophagectomy. Dis Esophagus 2018;31. [PMID: 29579257 DOI: 10.1093/dote/dox127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
396 Abe T, Numata Y, Higaki E, Hosoi T, Shimizu Y. A novel laparoscopic assisted mediastinal dissection with gastric tube inversion technique for gastric tube cancer reconstructed through a retrosternal route. Ann Gastroenterol Surg 2021;5:720-5. [PMID: 34585056 DOI: 10.1002/ags3.12473] [Reference Citation Analysis]
397 Thakur B, Devkota M, Chaudhary M. Management of Locally Advanced Esophageal Cancer. JNMA J Nepal Med Assoc 2021;59:409-16. [PMID: 34508544 DOI: 10.31729/jnma.4299] [Reference Citation Analysis]
398 Kawamoto T, Shikama N, Oshima M, Kosugi Y, Tsurumaru M, Sasai K. Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer. J Geriatr Oncol 2020;11:675-9. [PMID: 31471169 DOI: 10.1016/j.jgo.2019.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
399 Hagiwara N, Matsutani T, Haruna T, Nomura T, Yoshida H. Pedunculated esophageal carcinoma endoscopically removed using SB knife Jr with detachable snare after neoadjuvant chemotherapy. Clin J Gastroenterol 2020;13:1036-40. [PMID: 32870482 DOI: 10.1007/s12328-020-01214-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Chen X, Cai S, Li B, Zhang X, Li W, Liang H, Cao X, Wang L, Wu Z. MicroRNA21 regulates the biological behavior of esophageal squamous cell carcinoma by targeting RASA1. Oncol Rep. 2019;41:1627-1637. [PMID: 30569149 DOI: 10.3892/or.2018.6944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
401 Satomi T, Kawano S, Inaba T, Nakagawa M, Mouri H, Yoshioka M, Tanaka S, Toyokawa T, Kobayashi S, Tanaka T, Kanzaki H, Iwamuro M, Kawahara Y, Okada H. Efficacy and safety of endoscopic submucosal dissection for gastric tube cancer: A multicenter retrospective study. World J Gastroenterol 2021; 27(11): 1043-1054 [PMID: 33776371 DOI: 10.3748/wjg.v27.i11.1043] [Reference Citation Analysis]
402 Izumi D, Yoshida N, Watanabe M, Shiraishi S, Ishimoto T, Kosumi K, Tokunaga R, Taki K, Higashi T, Harada K, Miyata T, Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yamashita Y, Baba H. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2016;51:788-95. [PMID: 26671045 DOI: 10.1007/s00535-015-1150-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
403 Huang B, Shi H, Gong X, Yu J, Xiao C, Zhou B, Liang Z, Li X. Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma. J Gastrointest Oncol 2021;12:2013-21. [PMID: 34790369 DOI: 10.21037/jgo-21-610] [Reference Citation Analysis]
404 Yamashita K, Katada N, Moriya H, Hosoda K, Mieno H, Katada C, Koizumi W, Hoshi K, Watanabe M. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Gen Thorac Cardiovasc Surg 2016;64:209-15. [DOI: 10.1007/s11748-016-0626-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
405 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan. Cancers (Basel) 2019;11:E993. [PMID: 31315281 DOI: 10.3390/cancers11070993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
406 Shiozaki A, Kudou M, Ichikawa D, Shimizu H, Arita T, Kosuga T, Konishi H, Komatsu S, Fujiwara H, Okamoto K, Kishimoto M, Marunaka Y, Otsuji E. Expression and role of anion exchanger 1 in esophageal squamous cell carcinoma. Oncotarget 2017;8:17921-35. [PMID: 28160546 DOI: 10.18632/oncotarget.14900] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
407 Saigusa S, Mohri Y, Tanaka K, Ohi M, Shimura T, Kitajima T, Ishino Y, Yasuda H, Okugawa Y, Toiyama Y, Inoue Y, Uchida K, Kusunoki M. Impact of extracapsular lymph node involvement on tumor progression in esophageal squamous cell carcinoma after neoadjuvant therapy and effects on lymph nodes induced by chemotherapy and chemoradiotherapy. Esophagus 2014;11:108-16. [DOI: 10.1007/s10388-014-0418-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
408 Ujiie N, Nakano T, Kamei T, Ichikawa H, Miyata G, Onodera K, Ohuchi N. Thoracoscopic esophagectomy for esophageal cancer with situs inversus totalis: a case report and literature review. Gen Thorac Cardiovasc Surg 2016;64:359-62. [PMID: 26984287 DOI: 10.1007/s11748-016-0639-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
409 Chen MQ, Chen C, Lu HJ, Xu BH. The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. J Thorac Dis. 2015;7:1749-1755. [PMID: 26623097 DOI: 10.3978/j.issn.2072-1439.2015.10.23] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
410 Yamamoto M, Ozawa S, Koyanagi K, Oguma J, Kazuno A, Ninomiya Y, Yatabe K, Kajiwara H. Effectiveness of neoadjuvant chemotherapy with etoposide and cisplatin followed by surgery for esophageal neuroendocrine carcinoma: a case report. J Thorac Dis 2018;10:E450-5. [PMID: 30069403 DOI: 10.21037/jtd.2018.05.170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
411 Sonoda A, Yoshida N, Baba H. ASO Author Reflections: Total Lesion Glycolysis Ratio in Positron Emission Tomography and Computed Tomography Images During Neoadjuvant Chemotherapy: Usefulness and Perspectives as an Evaluation Tool for the Effect of Neoadjuvant Treatment on Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2020;27:806-7. [PMID: 32623607 DOI: 10.1245/s10434-020-08796-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Yamamura K, Izumi D, Kandimalla R, Sonohara F, Baba Y, Yoshida N, Kodera Y, Baba H, Goel A. Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. Clin Cancer Res 2019;25:6170-9. [PMID: 31358543 DOI: 10.1158/1078-0432.CCR-19-0318] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
413 Li J, Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 2021;12:2293-9. [PMID: 34254738 DOI: 10.1111/1759-7714.14069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
414 Kumabe A, Fukada J, Kota R, Koike N, Shiraishi Y, Seki S, Yoshida K, Kitagawa Y, Shigematsu N. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma. Dis Esophagus 2018;31. [PMID: 29228166 DOI: 10.1093/dote/dox138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
415 Esaki M, Suzuki S, Hayashi Y, Yokoyama A, Abe S, Hosokawa T, Tsuruta S, Minoda Y, Hata Y, Ogino H, Akiho H, Ihara E, Ogawa Y. Propensity score-matching analysis to compare clinical outcomes of endoscopic submucosal dissection for early gastric cancer in the postoperative and non-operative stomachs. BMC Gastroenterol 2018;18:125. [PMID: 30081824 DOI: 10.1186/s12876-018-0855-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
416 Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, Muguruma K, Yashiro M, Hirakawa K, Ohira M. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer 2016;16:722. [PMID: 27599460 DOI: 10.1186/s12885-016-2696-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 93] [Article Influence: 13.8] [Reference Citation Analysis]
417 Mine S, Watanabe M, Okamura A, Imamura Y, Kajiyama Y, Sano T. Superior Thoracic Aperture Size is Significantly Associated with Cervical Anastomotic Leakage After Esophagectomy. World J Surg 2017;41:2598-604. [DOI: 10.1007/s00268-017-4047-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
418 Udagawa H. Past, present, and future of three-field lymphadenectomy for thoracic esophageal cancer. Ann Gastroenterol Surg 2020;4:324-30. [PMID: 32724875 DOI: 10.1002/ags3.12338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
419 Ohi M, Toiyama Y, Omura Y, Ichikawa T, Yasuda H, Okugawa Y, Fujikawa H, Okita Y, Yoshiyama S, Hiro J, Araki T, Kusunoki M. Risk factors and measures of pulmonary complications after thoracoscopic esophagectomy for esophageal cancer. Surg Today 2019;49:176-86. [DOI: 10.1007/s00595-018-1721-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
420 Akiyama Y, Iwaya T, Endo F, Nikai H, Sato K, Baba S, Chiba T, Kimura T, Takahara T, Nitta H, Otsuka K, Mizuno M, Kimura Y, Koeda K, Sasaki A. Evaluation of the need for routine feeding jejunostomy for enteral nutrition after esophagectomy. J Thorac Dis. 2018;10:6854-6862. [PMID: 30746231 DOI: 10.21037/jtd.2018.11.97] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
421 Inoue Y, Oba A, Ono Y, Sato T, Ito H, Takahashi Y. Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy-Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers (Basel) 2021;13:1818. [PMID: 33920314 DOI: 10.3390/cancers13081818] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
422 Li XK, Xu Y, Cong ZZ, Luo J, Zhou H, Ji SG, Diao YF, Wu WJ, Qiang Y, Qian JJ, Shen Y. Modified Collard versus end-to-side hand-sewn anastomosis for cervical anastomosis after McKeown esophagectomy. Thorac Cancer 2020;11:2909-15. [PMID: 32833352 DOI: 10.1111/1759-7714.13630] [Reference Citation Analysis]
423 Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, Kitagawa Y. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol 2015;22:302-10. [PMID: 24952029 DOI: 10.1245/s10434-014-3857-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
424 Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, Geh JI, Griffiths EA. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. Ann Surg. 2017;265:481-491. [PMID: 27429017 DOI: 10.1097/sla.0000000000001905] [Cited by in Crossref: 80] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
425 Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol 2021;17:1143-53. [PMID: 33533655 DOI: 10.2217/fon-2020-0969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
426 Hao W, Shen Y, Feng M, Wang H, Lin M, Fang Y, Tan L. Aspirin acts in esophageal cancer: a brief review. J Thorac Dis 2018;10:2490-7. [PMID: 29850157 DOI: 10.21037/jtd.2018.03.110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
427 Nagaki Y, Motoyama S, Yamaguchi T, Hoshizaki M, Sato Y, Sato T, Koizumi Y, Wakita A, Kawakita Y, Imai K, Nanjo H, Watanabe H, Imai Y, Minamiya Y, Kuba K. m6 A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis. Genes Cells 2020;25:547-61. [PMID: 32449584 DOI: 10.1111/gtc.12792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
428 Duan J, Deng T, Ying G, Huang D, Zhang H, Zhou L, Bai M, Li H, Yang H, Qu Y, Wang X, Ba Y. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy. Jpn J Clin Oncol 2016;46:336-43. [PMID: 26819278 DOI: 10.1093/jjco/hyv206] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
429 Yamashita K, Makino T, Yamasaki M, Tanaka K, Hara T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer. Dis Esophagus 2017;30:1-8. [PMID: 28881906 DOI: 10.1093/dote/dox096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
430 Zhang Z, Hong ZN, Xie S, Lin W, Lin Y, Zhu J, Yang X, Lin Z, Lin J, Kang M. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1). Ann Transl Med 2021;9:1623. [PMID: 34926667 DOI: 10.21037/atm-21-5381] [Reference Citation Analysis]
431 Baba Y, Baba H. Gene-expression signature may be useful for the prediction of lymph node metastasis in esophageal cancer. Ann Transl Med 2018;6:230. [PMID: 30023393 DOI: 10.21037/atm.2018.05.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
432 Moremen JR, Skopelja EN, Ceppa DP. The role of induction therapy. J Thorac Dis 2014;6 Suppl 3:S309-13. [PMID: 24876935 DOI: 10.3978/j.issn.2072-1439.2014.03.10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
433 Shimada A, Tsushima T, Tsubosa Y, Booka E, Takebayashi K, Niihara M, Isaka M, Ohde Y, Machida N, Onozawa Y, Yasui H, Takeuchi H, Kitagawa Y. Validity of Surgical Resection for Lymph Node or Pulmonary Recurrence of Esophageal Cancer After Definitive Treatment. World J Surg 2019;43:1286-93. [PMID: 30675631 DOI: 10.1007/s00268-018-04904-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
434 Atsumi K, Nakamura K, Abe K, Hirakawa M, Shioyama Y, Sasaki T, Baba S, Isoda T, Ohga S, Yoshitake T, Shinoto M, Asai K, Honda H. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. J Radiat Res 2013;54:890-8. [PMID: 23520267 DOI: 10.1093/jrr/rrt021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
435 Baba Y, Yoshida N, Shigaki H, Iwatsuki M, Miyamoto Y, Sakamoto Y, Watanabe M, Baba H. Prognostic Impact of Postoperative Complications in 502 Patients With Surgically Resected Esophageal Squamous Cell Carcinoma: A Retrospective Single-institution Study. Ann Surg. 2016;264:305-311. [PMID: 26670288 DOI: 10.1097/SLA.0000000000001510] [Cited by in Crossref: 87] [Cited by in F6Publishing: 40] [Article Influence: 17.4] [Reference Citation Analysis]
436 Nomura H, Tsuji D, Ueno S, Kojima T, Fujii S, Yano T, Daiko H, Demachi K, Itoh K, Kawasaki T. Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer. Invest New Drugs 2021. [PMID: 34792690 DOI: 10.1007/s10637-021-01199-y] [Reference Citation Analysis]
437 Sheng L, Ji Y, Du X. Perineural invasion correlates with postoperative distant metastasis and poor overall survival in patients with PT1-3N0M0 esophageal squamous cell carcinoma. Onco Targets Ther 2015;8:3153-7. [PMID: 26604784 DOI: 10.2147/OTT.S90909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
438 Wang H, Tan L. Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus-Reply. JAMA Surg 2021. [PMID: 34550313 DOI: 10.1001/jamasurg.2021.4533] [Reference Citation Analysis]
439 Yoshida N, Baba Y, Shigaki H, Harada K, Iwatsuki M, Sakamoto Y, Miyamoto Y, Kurashige J, Kosumi K, Tokunaga R, Watanabe M, Baba H. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma. Int J Clin Oncol 2016;21:1071-8. [DOI: 10.1007/s10147-016-0994-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
440 Kakuta T, Kosugi S, Kanda T, Ishikawa T, Hanyu T, Suzuki T, Wakai T. Prognostic factors and causes of death in patients cured of esophageal cancer. Ann Surg Oncol. 2014;21:1749-1755. [PMID: 24510184 DOI: 10.1245/s10434-014-3499-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
441 Yoshida N, Baba Y, Hiyoshi Y, Shigaki H, Kurashige J, Sakamoto Y, Miyamoto Y, Iwatsuki M, Ishimoto T, Kosumi K, Sugihara H, Harada K, Tokunaga R, Izumi D, Watanabe M, Baba H. Duration of Smoking Cessation and Postoperative Morbidity After Esophagectomy for Esophageal Cancer: How Long Should Patients Stop Smoking Before Surgery? World J Surg 2016;40:142-7. [DOI: 10.1007/s00268-015-3236-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
442 Sugimura K, Motoori M, Yano M, Ishihara R, Hanaoka N, Miyoshi N, Akita H, Goto K, Kobayashi S, Takahashi H, Omori T, Noura S, Ohue M, Fujiwara Y, Sakon M. Endoscopic steroid injection reduced frequency of repeat dilation in patients with anastomotic stenosis after esophagectomy. Esophagus 2016;13:62-7. [DOI: 10.1007/s10388-015-0495-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
443 Tanaka T, Kinoshita Y, Udagawa H, Ueno M, Ehara K, Haruta S, Kaida S, Nakagawa M. Efficacy and safety of docetaxel/cisplatin/5-fluorouracil preoperative combination chemotherapy in esophageal cancer patients with extended lymph node metastases. Esophagus 2012;9:99-104. [DOI: 10.1007/s10388-012-0312-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
444 Takahashi T, Kaneoka Y, Maeda A, Takayama Y, Seita K. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma. Updates Surg 2021. [PMID: 34559400 DOI: 10.1007/s13304-021-01167-4] [Reference Citation Analysis]
445 Tan X, Peng H, Gu P, Chen M, Wang Y. Prognostic Significance of the L3 Skeletal Muscle Index and Advanced Lung Cancer Inflammation Index in Elderly Patients with Esophageal Cancer. Cancer Manag Res 2021;13:3133-43. [PMID: 33859499 DOI: 10.2147/CMAR.S304996] [Reference Citation Analysis]
446 Mayanagi S, Tsubosa Y, Omae K, Niihara M, Uchida T, Tsushima T, Yokota T, Sato H, Naito T, Yasui H. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. Ann Surg Oncol 2017;24:3741-7. [PMID: 28861809 DOI: 10.1245/s10434-017-6020-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
447 Nakaya S, Ogawa R, Hayakawa S, Fujihata S, Okubo T, Sagawa H, Tanaka T, Takahashi H, Matsuo Y, Takiguchi S. Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma. World J Surg Oncol 2021;19:217. [PMID: 34281546 DOI: 10.1186/s12957-021-02290-7] [Reference Citation Analysis]
448 Kobayashi S, Nagata Y, Tokai H, Ito M, Fujioka H. Multidisciplinary therapy for granulocyte-colony-stimulating factor producing carcinosarcoma of the esophagus: report of a case. Clin Case Rep 2015;3:681-5. [PMID: 26331012 DOI: 10.1002/ccr3.295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
449 Ikebe M, Morita M, Yamamoto M, Toh Y. Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management. Gen Thorac Cardiovasc Surg 2016;64:386-94. [DOI: 10.1007/s11748-016-0655-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
450 Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP. Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation? World J Gastroenterol 2017; 23(46): 8193-8199 [PMID: 29290655 DOI: 10.3748/wjg.v23.i46.8193] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
451 Yamamoto S, Kato K. Immuno-oncology for esophageal cancer. Future Oncol 2020;16:2673-81. [PMID: 32777942 DOI: 10.2217/fon-2020-0545] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
452 Tsujimoto H, Hiraki S, Takahata R, Nomura S, Ito N, Kanematsu K, Horiguchi H, Aosasa S, Yamamoto J, Hase K. Laparoscopic jejunostomy for obstructing upper gastrointestinal malignancies. Mol Clin Oncol. 2015;3:1307-1310. [PMID: 26807238 DOI: 10.3892/mco.2015.612] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
453 Hirohata R, Hamai Y, Emi M, Kurokawa T, Yoshikawa T, Ohsawa M, Tadokoro K, Okada M. Prediction of the tumor response and survival based on computed tomography in esophageal squamous cell carcinoma after trimodality therapy. Surg Today 2021;51:1496-505. [PMID: 33797639 DOI: 10.1007/s00595-021-02277-7] [Reference Citation Analysis]
454 Sato Y, Motoyama S, Wada Y, Wakita A, Kawakita Y, Nagaki Y, Terata K, Imai K, Anbai A, Hashimoto M, Minamiya Y. Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis. Cancers (Basel) 2021;13:983. [PMID: 33652817 DOI: 10.3390/cancers13050983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
455 Kano K, Aoyama T, Maezawa Y, Hayashi T, Yamada T, Tamagawa H, Sato T, Cho H, Yoshikawa T, Rino Y, Masuda M, Oshima T, Ogata T. Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. In Vivo 2019;33:587-94. [PMID: 30804146 DOI: 10.21873/invivo.11515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
456 Okamura A, Yamashita K, Kozuki R, Takahashi K, Toihata T, Imamura Y, Mine S, Watanabe M. Inflammatory response and recurrence after minimally invasive esophagectomy. Langenbecks Arch Surg 2019;404:761-9. [DOI: 10.1007/s00423-019-01818-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
457 Sudo N, Ichikawa H, Muneoka Y, Hanyu T, Kano Y, Ishikawa T, Hirose Y, Miura K, Shimada Y, Nagahashi M, Sakata J, Kobayashi T, Bamba T, Nakagawa S, Kosugi SI, Wakai T. Clinical Utility of ypTNM Stage Grouping in the 8th Edition of the American Joint Committee on Cancer TNM Staging System for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021;28:650-60. [PMID: 33025354 DOI: 10.1245/s10434-020-09181-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
458 Li B, Yang Y, Sun Y, Hua R, Zhang X, Guo X, Gu H, Ye B, Li Z, Mao T. Minimally invasive esophagectomy for esophageal squamous cell carcinoma-Shanghai Chest Hospital experience. J Thorac Dis 2018;10:3800-7. [PMID: 30069380 DOI: 10.21037/jtd.2018.06.75] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
459 Miki Y, Toyokawa T, Kubo N, Tamura T, Sakurai K, Tanaka H, Muguruma K, Yashiro M, Hirakawa K, Ohira M. C-Reactive Protein Indicates Early Stage of Postoperative Infectious Complications in Patients Following Minimally Invasive Esophagectomy. World J Surg 2017;41:796-803. [DOI: 10.1007/s00268-016-3803-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
460 Takata A, Takiguchi S, Miyazaki Y, Miyata H, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Mori M, Kangawa K, Doki Y. Randomized Phase II Study of the Anti-inflammatory Effect of Ghrelin During the Postoperative Period of Esophagectomy. Ann Surg 2015;262:230-6. [PMID: 25361222 DOI: 10.1097/SLA.0000000000000986] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
461 Matsuda S, Tsubosa Y, Sato H, Takebayashi K, Kawamorita K, Mori K, Niihara M, Tsushima T, Yokota T, Onozawa Y, Yasui H, Takeuchi H, Kitagawa Y. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Dis Esophagus 2017;30:1-8. [PMID: 26919154 DOI: 10.1111/dote.12473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
462 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
463 Kitagawa H, Namikawa T, Munekage M, Fujisawa K, Munekgae E, Kobayashi M, Hanazaki K. Outcomes of thoracoscopic esophagectomy in prone position with laparoscopic gastric mobilization for esophageal cancer. Langenbecks Arch Surg 2016;401:699-705. [PMID: 27225750 DOI: 10.1007/s00423-016-1446-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
464 Ushiku H, Yamashita K, Katoh H, Ema A, Minatani N, Kikuchi M, Kojo K, Yokoi K, Tanaka T, Nishizawa N, Ishii S, Hosoda K, Moriya H, Mieno H, Katada N, Kikuchi S, Watanabe M. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma. Dis Esophagus 2017;30:1-9. [PMID: 27629777 DOI: 10.1111/dote.12496] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
465 Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Hara J, Yamamura T, Inoue M. Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma. Mol Clin Oncol 2013;1:773-9. [PMID: 24649245 DOI: 10.3892/mco.2013.128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
466 Ogura M, Takeuchi H, Kawakubo H, Nishi T, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, Miyasho T, Yamada S, Kitagawa Y. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. Surgery 2013;154:512-20. [DOI: 10.1016/j.surg.2013.06.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
467 Motoyama S, Maeda E, Yano M, Yasuda T, Ohira M, Doki Y, Toh Y, Higashi T, Matsubara H; Japan Esophageal Society. Appropriateness of the institute certification system for esophageal surgeries by the Japan Esophageal Society: evaluation of survival outcomes using data from the National Database of Hospital-Based Cancer Registries in Japan. Esophagus 2019;16:114-21. [PMID: 30324431 DOI: 10.1007/s10388-018-0646-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
468 Okamura A, Matsuda S, Mayanagi S, Kanamori J, Imamura Y, Irino T, Kawakubo H, Mine S, Takeuchi H, Kitagawa Y, Watanabe M. Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021;28:1209-16. [PMID: 32524457 DOI: 10.1245/s10434-020-08716-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
469 Garg PK, Sharma J, Jakhetiya A, Goel A, Gaur MK. Preoperative therapy in locally advanced esophageal cancer. World J Gastroenterol 2016; 22(39): 8750-8759 [PMID: 27818590 DOI: 10.3748/wjg.v22.i39.8750] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
470 Watanabe A, Taniguchi M, Kimura Y, Kikkawa T, Hosokawa M. Larynx-preserving hybrid surgery with endoscopic laryngopharyngeal surgery and open surgery for cervical esophageal cancer invading pharynx. Diseases of the Esophagus 2020;33:doaa020. [DOI: 10.1093/dote/doaa020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
471 Wang Q, Lang J, Li T, Peng L, Dai W, Jiang Y, Xie T, Fang Q, Wang Y, Wu L, Cao B, Han Y. Postoperative adjuvant chemotherapy versus chemoradiotherapy for node-positive esophageal squamous cell carcinoma: a propensity score-matched analysis. Radiat Oncol 2020;15:119. [PMID: 32448253 DOI: 10.1186/s13014-020-01557-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
472 Kubota K, Yoshida M, Kuroda J, Okada A, Ohta K, Kitajima M. Application of the HyperEye Medical System for esophageal cancer surgery: a preliminary report. Surg Today. 2013;43:215-220. [PMID: 22782594 DOI: 10.1007/s00595-012-0251-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
473 Li X, Zhang J, Ye C, Zhu J, Guo K, Guo Y. Impact of chemotherapy and radiotherapy on the survival of elderly esophageal cancer patients undergoing surgery: a SEER database analysis. BMC Gastroenterol 2021;21:430. [PMID: 34794384 DOI: 10.1186/s12876-021-02016-9] [Reference Citation Analysis]
474 Oguma J, Ozawa S, Kazuno A, Nitta M, Ninomiya Y, Kajiwara H. Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma. Oncol Lett 2018;15:3100-8. [PMID: 29435043 DOI: 10.3892/ol.2017.7666] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
475 Koterazawa Y, Oshikiri T, Takiguchi G, Urakawa N, Hasegawa H, Yamamoto M, Kanaji S, Yamashita K, Matsuda T, Nakamura T, Suzuki S, Kakeji Y. Severe weight loss after minimally invasive oesophagectomy is associated with poor survival in patients with oesophageal cancer at 5 years. BMC Gastroenterol 2020;20:407. [PMID: 33272220 DOI: 10.1186/s12876-020-01543-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
476 Sato Y, Motoyama S, Nanjo H, Ito S, Yoshino K, Sasaki T, Kuribayashi K, Nagaki Y, Imai K, Saito H, Minamiya Y, Ogawa J. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy. Ann Surg Oncol 2013;20:3044-51. [PMID: 23645481 DOI: 10.1245/s10434-013-2983-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
477 Miyawaki Y, Sato H, Oya S, Sugita H, Hirano Y, Sakuramoto S, Okamotom K, Yamaguchim S, Koyama I. Clinical impact of abdominal versus mediastinal metastases as a prognostic factor for poor outcomes following esophageal cancer surgery: a retrospective study. BMC Cancer 2021;21:725. [PMID: 34162359 DOI: 10.1186/s12885-021-08484-2] [Reference Citation Analysis]
478 Hayashi M, Kawakubo H, Fukuda K, Mayanagi S, Nakamura R, Suda K, Hayashida T, Wada N, Kitagawa Y. THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis. J Gene Med 2019;21:e3135. [PMID: 31656051 DOI: 10.1002/jgm.3135] [Reference Citation Analysis]
479 Miyata H, Yamasaki M, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Annals of Surgery 2015;262:280-5. [DOI: 10.1097/sla.0000000000000933] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
480 Matsuura N, Tanaka K, Yamasaki M, Yamashita K, Saito T, Makino T, Yamamoto K, Takahashi T, Kurokawa Y, Nakajima K, Eguchi H, Nakagawa H, Doki Y. NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer. Cancer Med 2021;10:3986-96. [PMID: 34042293 DOI: 10.1002/cam4.3933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
481 Oguma J, Ozawa S, Kazuno A, Yamasaki Y, Ninomiya Y. Gastrointestinal perforation during neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in patients with esophageal cancer: a report of two cases. Esophagus 2016;13:374-7. [DOI: 10.1007/s10388-016-0537-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
482 Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li H, Pan Y, Peng Y, Yao X, Liu P, Sun Y, Li B, Zhang Y. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis 2021;13:3518-28. [PMID: 34277047 DOI: 10.21037/jtd-21-340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
483 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer 2019;10:1097-102. [PMID: 30854116 DOI: 10.7150/jca.29353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
484 Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. Cancer Sci 2018;109:785-93. [PMID: 29285832 DOI: 10.1111/cas.13481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
485 Wong I, Law S. The management of mid & proximal oesophageal squamous cell carcinoma. Best Pract Res Clin Gastroenterol 2018;36-37:85-90. [PMID: 30551861 DOI: 10.1016/j.bpg.2018.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
486 Zheng Y, Li Y, Qin J, Xing W, Liu X, Sun H, Chen X. Dysphagia predict the response to second cycle neoadjuvant chemotherapy in first cycle no response esophageal carcinoma. J Thorac Dis 2019;11:4135-43. [PMID: 31737296 DOI: 10.21037/jtd.2019.10.02] [Reference Citation Analysis]
487 Saeki H, Morita M, Tsuda Y, Hidaka G, Kasagi Y, Kawano H, Otsu H, Ando K, Kimura Y, Oki E, Kusumoto T, Maehara Y. Multimodal Treatment Strategy for Clinical T3 Thoracic Esophageal Cancer. Ann Surg Oncol 2013;20:4267-73. [DOI: 10.1245/s10434-013-3192-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
488 Ishihara R, Yamamoto S, Iishi H, Nagai K, Matui F, Kawada N, Ohta T, Kanzaki H, Hanafusa M, Hanaoka N, Takeuchi Y, Higashino K, Uedo N, Sugimoto N, Kawaguchi Y, Nishiyama K, Motoori M, Yano M, Hosoki T. Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int J Clin Oncol 2012;17:225-32. [PMID: 21735356 DOI: 10.1007/s10147-011-0278-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
489 Le Bras GF, Farooq MH, Falk GW, Andl CD. Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res 2016;113:236-44. [PMID: 27565381 DOI: 10.1016/j.phrs.2016.08.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
490 Miyawaki Y, Nakajima Y, Kawada K, Okada T, Tokairin Y, Kawano T. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Dis Esophagus 2017;30:1-8. [PMID: 27001629 DOI: 10.1111/dote.12485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
491 Hashimoto T, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Morii E, Mori M, Doki Y. The Pattern of Residual Tumor After Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer and Its Clinical Significance. Ann Surg 2020;271:875-84. [PMID: 30829694 DOI: 10.1097/SLA.0000000000003129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
492 Matsuura N, Yamasaki M, Yamashita K, Tanaka K, Makino T, Saito T, Yamamoto K, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Eguchi H, Doki Y. The role of adjuvant chemotherapy in esophageal cancer patients after neoadjuvant chemotherapy plus surgery. Esophagus 2021;18:559-65. [PMID: 33580452 DOI: 10.1007/s10388-020-00811-z] [Reference Citation Analysis]
493 Chan L, Huang Y, Chen T. Cancer-targeted tri-block copolymer nanoparticles as payloads of metal complexes to achieve enhanced cancer theranosis. J Mater Chem B 2016;4:4517-25. [DOI: 10.1039/c6tb00514d] [Cited by in Crossref: 14] [Article Influence: 2.3] [Reference Citation Analysis]
494 Hoshimoto S, Takeuchi H, Ono S, Sim MS, Huynh JL, Huang SK, Marzese DM, Kitagawa Y, Hoon DS. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. J Thorac Oncol 2015;10:509-17. [PMID: 25514805 DOI: 10.1097/JTO.0000000000000441] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
495 Wong IY, Law S. Surgery in the era of neoadjuvant therapy for cancer of the esophagus. Esophagus 2016;13:105-9. [DOI: 10.1007/s10388-016-0523-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
496 Miyagaki H, Yamasaki M, Miyata H, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Fujiwara Y, Ishii H, Tanaka F, Mori M, Doki Y. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. Br J Cancer 2012;106:947-54. [PMID: 22333595 DOI: 10.1038/bjc.2012.35] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
497 Miyawaki Y, Sato H, Fujiwara N, Oya S, Sugita H, Hirano Y, Yamane T, Sakuramoto S, Okamoto K, Yamaguchi S, Koyama I. Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study. Int J Clin Oncol 2020;25:561-9. [PMID: 31867680 DOI: 10.1007/s10147-019-01606-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
498 Minami T, Yuasa N, Miyake H, Takeuchi E, Nagai H, Ito M, Kiriyama A, Miyata K. MIB-1 index is unlikely to predict relapse-free survival in patients who underwent R0-esophagectomy for esophageal squamous cell carcinoma. Dis Esophagus 2018;31. [PMID: 29272372 DOI: 10.1093/dote/dox145] [Reference Citation Analysis]
499 Kaneko Y, Saito S, Takahashi K, Kanamaru R, Hosoya Y, Yamaguchi H, Kitayama J, Niki T, Lefor AK, Sata N. Neuroendocrine carcinoma of the esophagus with an adenocarcinoma component. Clin J Gastroenterol 2019;12:534-8. [PMID: 31134449 DOI: 10.1007/s12328-019-00995-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
500 Kurogochi T, Honda M, Yamashita K, Hayami M, Okamura A, Imamura Y, Mine S, Watanabe M. Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma. Surg Today 2019;49:150-7. [DOI: 10.1007/s00595-018-1718-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
501 Matsuda S, Takeuchi H, Fukuda K, Nakamura R, Takahashi T, Wada N, Kawakubo H, Saikawa Y, Omori T, Kitagawa Y. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment: Plasma fibrinogen in esophageal cancer. Dis Esophagus 2014;27:654-61. [DOI: 10.1111/dote.12115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
502 Ozawa H, Kawakubo H, Takeuchi M, Ishibashi Y, Matsuda S, Mayanagi S, Takemura R, Irino T, Fukuda K, Nakamura R, Wada N, Kitagawa Y. Prognostic Significance of the Number and Extent of Metastatic Lymph Nodes in Patients with Esophageal Cancer: Comparison of the Union for International Cancer Control 8th Edition and Japan Esophageal Society Japanese Classification of Esophageal Cancer 11th Edition Classifications for Esophageal Cancer. Ann Surg Oncol 2021. [PMID: 33748898 DOI: 10.1245/s10434-020-09545-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
503 Fujita K, Motoyama S, Sato Y, Wakita A, Nagaki Y, Minamiya Y, Miura M. Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy. Esophagus 2021. [PMID: 34347217 DOI: 10.1007/s10388-021-00865-7] [Reference Citation Analysis]
504 Leng XF, Daiko H, Han YT, Mao YS. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma. Ann N Y Acad Sci 2020;1482:213-24. [PMID: 33067818 DOI: 10.1111/nyas.14508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
505 Sawada R, Maehara R, Oshikiri T, Nakamura T, Itoh T, Kodama Y, Kakeji Y, Zen Y. MDM2 copy number increase: a poor prognostic, molecular event in esophageal squamous cell carcinoma. Hum Pathol 2019;89:1-9. [PMID: 31004651 DOI: 10.1016/j.humpath.2019.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
506 Shimizu D, Yuasa N, Miyake H, Takeuchi E, Miyata K, Itoh S. Clinical significance of SUVmax on preoperative 18F-fluorodeoxyglucose positron emission tomography in patients who underwent R0-esophagectomy for esophageal cancer. Nagoya J Med Sci 2018;80:401-9. [PMID: 30214089 DOI: 10.18999/nagjms.80.3.401] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
507 Sakamoto K, Takeda S, Kanekiyo S, Nishiyama M, Kitahara M, Ueno T, Yamamoto S, Yoshino S, Hazama S, Okayama N, Nagano H. Association of tumor necrosis factor-α polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancer. Mol Clin Oncol 2017;6:125-9. [PMID: 28123745 DOI: 10.3892/mco.2016.1081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
508 Yamashita K, Watanabe M, Mine S, Kurogochi T, Okamura A, Hayami M, Imamura Y. Patterns and Outcomes of Recurrent Esophageal Cancer After Curative Esophagectomy. World J Surg 2017;41:2337-44. [PMID: 28432391 DOI: 10.1007/s00268-017-4024-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
509 Qiang F, Guangguo R, Yongtao H, Dandan D, Hong Y. Multidrug resistance in primary tumors and metastases in patients with esophageal squamous cell carcinoma. Pathol Oncol Res 2013;19:641-8. [PMID: 23508648 DOI: 10.1007/s12253-013-9623-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
510 Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y, Muto M. Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology. 2015;149:1700-1715. [PMID: 26376349 DOI: 10.1053/j.gastro.2015.08.054] [Cited by in Crossref: 243] [Cited by in F6Publishing: 257] [Article Influence: 34.7] [Reference Citation Analysis]
511 Tachimori Y, Ozawa S, Numasaki H, Matsubara H, Shinoda M, Toh Y, Udagawa H, Fujishiro M, Oyama T, Uno T; Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:1-7. [PMID: 26752982 DOI: 10.1007/s10388-015-0515-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 8.7] [Reference Citation Analysis]
512 Sugawara K, Yamashita H, Uemura Y, Yagi K, Nishida M, Aikou S, Nomura S, Seto Y. Preoperative lymph node status on computed tomography influences the survival of pT1b, T2 and T3 esophageal squamous cell carcinoma. Surg Today 2019;49:378-86. [PMID: 30467719 DOI: 10.1007/s00595-018-1741-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
513 Okamoto K, Ninomiya I, Yamaguchi T, Terai S, Nakanuma S, Kinoshita J, Makino I, Nakamura K, Miyashita T, Tajima H, Takamura H, Fushida S, Ohta T. Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer. Esophagus 2019;16:207-13. [PMID: 30600487 DOI: 10.1007/s10388-018-00655-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
514 Booka E, Haneda R, Ishii K, Tsubosa Y. ASO Author Reflections: The Impact of Preoperative Chemotherapy on Survival After Esophagectomy in Elderly Patients with Esophageal Cancer. Ann Surg Oncol 2021;28:1796-7. [PMID: 32860173 DOI: 10.1245/s10434-020-09078-1] [Reference Citation Analysis]
515 Petrelli F, Tomasello G, Barni S. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. European Journal of Cancer 2017;76:8-16. [DOI: 10.1016/j.ejca.2017.01.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
516 Kubo N, Sakurai K, Tamura T, Toyokawa T, Tanaka H, Muguruma K, Yashiro M, Ohira M. The impact of geriatric nutritional risk index on surgical outcomes after esophagectomy in patients with esophageal cancer. Esophagus 2019;16:147-54. [PMID: 30311102 DOI: 10.1007/s10388-018-0644-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
517 Uemura N, Kondo T. Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer. World J Gastrointest Pathophysiol 2014; 5(3): 322-334 [PMID: 25133032 DOI: 10.4291/wjgp.v5.i3.322] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
518 Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol 2013;43:608-15. [PMID: 23585687 DOI: 10.1093/jjco/hyt048] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
519 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
520 Kubota K, Kuroda J, Yoshida M, Okada A, Deguchi T, Kitajima M. Preoperative oral supplementation support in patients with esophageal cancer. J Nutr Health Aging 2014;18:437-40. [DOI: 10.1007/s12603-014-0018-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
521 Yan W, Zhao P, Fu H, Lin Y, Li Z, Dai L, Yang Y, Kang X, Chen KN. Survival After Induction Chemotherapy and Esophagectomy Is Not Improved by Adjuvant Chemotherapy. Ann Thorac Surg 2019;108:1505-13. [PMID: 31233722 DOI: 10.1016/j.athoracsur.2019.04.106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
522 Kobayashi T, Makino T, Yamashita K, Saito T, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Morii E, Eguchi H, Doki Y. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation. Br J Cancer 2021;125:1523-32. [PMID: 34599296 DOI: 10.1038/s41416-021-01561-0] [Reference Citation Analysis]
523 Matsuda S, Kawakubo H, Irino T, Kitagawa Y. Role sharing between minimally invasive oesophagectomy and organ preservation approach for surgically resectable advanced oesophageal cancer. Jpn J Clin Oncol 2021:hyab192. [PMID: 34891170 DOI: 10.1093/jjco/hyab192] [Reference Citation Analysis]
524 Sato H, Miyawaki Y, Lee S, Sugita H, Sakuramoto S, Tsubosa Y. Effectiveness and safety of a newly introduced multidisciplinary perioperative enhanced recovery after surgery protocol for thoracic esophageal cancer surgery. Gen Thorac Cardiovasc Surg 2021. [PMID: 34596825 DOI: 10.1007/s11748-021-01717-y] [Reference Citation Analysis]
525 Ohkura Y, Ueno M, Udagawa H. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World J Surg Oncol 2019;17:125. [PMID: 31315622 DOI: 10.1186/s12957-019-1665-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
526 Yoshida N, Baba Y, Miyamoto Y, Iwatsuki M, Hiyoshi Y, Ishimoto T, Imamura Y, Watanabe M, Baba H. Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety. Ann Surg Oncol 2018;25:2434-40. [PMID: 29876696 DOI: 10.1245/s10434-018-6552-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
527 Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Ann Thorac Cardiovasc Surg. 2017;23:1-11. [PMID: 28003586 DOI: 10.5761/atcs.ra.16-00162] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 13.8] [Reference Citation Analysis]
528 Hirose T, Yamamoto S, Kato K. Emerging data on nivolumab for esophageal squamous cell carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:845-54. [PMID: 34251958 DOI: 10.1080/17474124.2021.1948836] [Reference Citation Analysis]
529 Watanabe K, Hikichi T, Nakamura J, Hashimoto M, Takagi T, Suzuki R, Sugimoto M, Kikuchi H, Konno N, Takasumi M, Sato Y, Irie H, Obara K, Ohira H. Clinical Outcomes and Adverse Events of Endoscopic Submucosal Dissection for Gastric Tube Cancer after Esophagectomy. Gastroenterol Res Pract 2019;2019:2836860. [PMID: 30944559 DOI: 10.1155/2019/2836860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
530 Mine S, Watanabe M, Imamura Y, Okamura A, Kurogochi T, Sano T. Clinical Significance of the Pre-therapeutic Nodal Size in Patients Undergoing Neo-Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma. World J Surg 2017;41:184-90. [PMID: 27468743 DOI: 10.1007/s00268-016-3675-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
531 Nonaka S, Oda I, Sato C, Abe S, Suzuki H, Yoshinaga S, Hokamura N, Igaki H, Tachimori Y, Taniguchi H, Kushima R, Saito Y. Endoscopic submucosal dissection for gastric tube cancer after esophagectomy. Gastrointest Endosc. 2014;79:260-270. [PMID: 24060521 DOI: 10.1016/j.gie.2013.07.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
532 Tsukada Y, Higashi T, Shimada H, Kikuchi Y, Terahara A. The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan. Int J Clin Oncol 2018;23:81-91. [PMID: 28795280 DOI: 10.1007/s10147-017-1178-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
533 Kaneko Y, Hisakura K, Ogawa K, Akashi Y, Ohara Y, Owada Y, Enomoto T, Furuya K, Moue S, Doi M, Takahashi K, Shimomura O, Hashimoto S, Sakamoto N, Maruyama T, Oda T. Long-term survival after esophagectomy with distal pancreatectomy for locally advanced esophageal cancer with pancreatic invasion: a case report. Surg Case Rep 2021;7:254. [PMID: 34905130 DOI: 10.1186/s40792-021-01338-w] [Reference Citation Analysis]
534 Murakami Y, Hamai Y, Emi M, Hihara J, Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Kimura T, Okada M, Nagata Y. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma. J Radiat Res 2018;59:616-24. [PMID: 29939306 DOI: 10.1093/jrr/rry047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
535 Harada K, Ida S, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, Izumi D, Ohuchi M, Nakamura K, Kiyozumi Y, Imamura Y, Iwatsuki M, Iwagami S, Miyamoto Y, Sakamoto Y, Yoshida N, Watanabe M, Baba H. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis Esophagus 2016;29:627-33. [PMID: 26123787 DOI: 10.1111/dote.12381] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 9.3] [Reference Citation Analysis]
536 Zhao Y, Wang Y, Shan L, Peng C, Zhang W, Zhao X. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. Sci Rep 2021;11:6800. [PMID: 33762694 DOI: 10.1038/s41598-021-86102-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
537 Miyata H, Yamasaki M, Makino T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. J Surg Oncol 2015;112:60-5. [PMID: 26179950 DOI: 10.1002/jso.23965] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
538 Bekkar S, Gronnier C, Renaud F, Duhamel A, Pasquer A, Théreaux J, Gagnière J, Meunier B, Collet D, Mariette C, Dhahri A, Lignier D, Cossé C, Regimbeau J, Luc G, Cabau M, Jougon J, Badic B, Lozach P, Bail JP, Cappeliez S, El Nakadi I, Lebreton G, Alves A, Flamein R, Pezet D, Pipitone F, Stan-iuga B, Contival N, Pappalardo E, Coueffe X, Msika S, Mantziari S, Demartines N, Hec F, Vanderbeken M, Tessier W, Briez N, Fredon F, Gainant A, Mathonnet M, Bigourdan JM, Mezoughi S, Ducerf C, Baulieux J, Mabrut J, Bigourdan JM, Baraket O, Poncet G, Adam M, Vaudoyer D, Jourdan Enfer P, Villeneuve L, Glehen O, Coste T, Fabre J, Marchal F, Frisoni R, Ayav A, Brunaud L, Bresler L, Cohen C, Aze O, Venissac N, Pop D, Mouroux J, Donici I, Prudhomme M, Felli E, Lisunfui S, Seman M, Godiris Petit G, Karoui M, Tresallet C, Ménégaux F, Vaillant J, Hannoun L, Malgras B, Lantuas D, Pautrat K, Pocard M, Valleur P, Lefevre JH, Chafai N, Balladur P, Lefrançois M, Parc Y, Paye F, Tiret E, Nedelcu M, Laface L, Perniceni T, Gayet B, Turner K, Filipello A, Porcheron J, Tiffet O, Kamlet N, Chemaly R, Klipfel A, Pessaux P, Brigand C, Rohr S, Carrère N, Da Re C, Dumont F, Goéré D, Elias D, Bertrand C. Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer. British Journal of Surgery 2016;103:855-62. [DOI: 10.1002/bjs.10121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
539 Nishi T, Takeuchi H, Matsuda S, Ogura M, Kawakubo H, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, Kitagawa Y. CXCR2 expression and postoperative complications affect long-term survival in patients with esophageal cancer. World J Surg Oncol 2015;13:232. [PMID: 26231560 DOI: 10.1186/s12957-015-0658-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
540 Sakai A, Nakashima Y, Miyashita Y, Ao T, Kimura Y, Shinto E, Oki E, Shimokawa M, Ueno H, Oda Y, Mori M. Histological categorisation of the desmoplastic reaction is a predictor of patient prognosis in oesophageal squamous cell carcinoma. Histopathology 2021;79:219-26. [PMID: 33595141 DOI: 10.1111/his.14357] [Reference Citation Analysis]
541 Kitagawa H, Namikawa T, Iwabu J, Fujisawa K, Kobayashi M, Hanazaki K. Outcomes of abdominal esophageal cancer patients who were treated with esophagectomy. Mol Clin Oncol 2018;8:286-91. [PMID: 29435289 DOI: 10.3892/mco.2017.1510] [Reference Citation Analysis]
542 Lu Y, Ma L, Qin J, Wang Z, Guo J, Zhao Y, Zhang H, Yan X, Liu H, Li H, Kamel IR, Qu J. The value of GRASP on DCE-MRI for assessing response to neoadjuvant chemotherapy in patients with esophageal cancer. BMC Cancer 2019;19:999. [PMID: 31651280 DOI: 10.1186/s12885-019-6247-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
543 Ono T. Review of clinical results of charged-particle therapy for esophageal cancer. Esophagus 2021;18:33-40. [PMID: 32654019 DOI: 10.1007/s10388-020-00759-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
544 Matsuda S, Tsubosa Y, Niihara M, Sato H, Takebayashi K, Kawamorita K, Mori K, Tsushima T, Yasui H, Takeuchi H, Kitagawa Y. Distribution of lymph node metastasis and clinical validity of gastric tube reconstruction in lower thoracic esophageal squamous cell carcinoma with gastric invasion. Ann Surg Oncol 2015;22:617-23. [PMID: 25164036 DOI: 10.1245/s10434-014-4017-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
545 Yamaguchi S, Kanetaka K, Kobayashi S, Nagata Y, Kinosita N, Fukuoka J, Murakami S, Fujita F, Takatsuki M, Eguchi S. Severe neutrophilic leukocytosis as a progression marker in granulocyte colony-stimulating factor-producing squamous cell carcinoma of the esophagus. Clin Case Rep 2017;5:688-93. [PMID: 28469877 DOI: 10.1002/ccr3.908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
546 Takahashi T, Yamahsita S, Matsuda Y, Kishino T, Nakajima T, Kushima R, Kato K, Igaki H, Tachimori Y, Osugi H, Nagino M, Ushijima T. ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. J Cancer Res Clin Oncol 2015;141:453-63. [PMID: 25273507 DOI: 10.1007/s00432-014-1841-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
547 Okumura H, Uchikado Y, Omoto I, Kita Y, Sasaki K, Arigami T, Uenosono Y, Matsushita D, Hiraki Y, Owaki T. The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases. Ann Surg Oncol. 2014;21:2845-2849. [PMID: 24728820 DOI: 10.1245/s10434-014-3688-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
548 Fujiwara H, Shiozaki A, Konishi H, Otsuji E. Transmediastinal approach for esophageal cancer: A new trend toward radical surgery. Asian J Endosc Surg 2019;12:30-6. [PMID: 30681280 DOI: 10.1111/ases.12687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
549 Taniyama Y, Murakami K, Yoshida N, Takahashi K, Matsubara H, Baba H, Kamei T. Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study. BMC Cancer 2021;21:1008. [PMID: 34496769 DOI: 10.1186/s12885-021-08747-y] [Reference Citation Analysis]
550 Shimoji H, Kinjo T, Karimata H, Nagahama M, Nishimaki T. Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors. Surg Today. 2013;Epub ahead of print. [PMID: 23963503 DOI: 10.1007/s00595-013-0700-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
551 Shoji Y, Takeuchi H, Fukuda K, Nakamura R, Wada N, Kawakubo H, Kitagawa Y. Air Bubble Sign: A New Screening Method for Anastomotic Leakage After Esophagectomy for Esophageal Cancer. Ann Surg Oncol 2018;25:1061-8. [PMID: 29318416 DOI: 10.1245/s10434-017-6327-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
552 Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy. J Transl Med 2019;17:1. [PMID: 30602370 DOI: 10.1186/s12967-018-1762-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
553 Tanaka E, Okabe H, Kinjo Y, Tsunoda S, Obama K, Hisamori S, Sakai Y. Advantages of the prone position for minimally invasive esophagectomy in comparison to the left decubitus position: better oxygenation after minimally invasive esophagectomy. Surg Today 2015;45:819-25. [PMID: 25387656 DOI: 10.1007/s00595-014-1061-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
554 Kosumi K, Baba Y, Yamashita K, Ishimoto T, Nakamura K, Ohuchi M, Kiyozumi Y, Izumi D, Tokunaga R, Harada K, Shigaki H, Kurashige J, Iwatsuki M, Sakamoto Y, Yoshida N, Watanabe M, Baba H. Monitoring sputum culture in resected esophageal cancer patients with preoperative treatment. Diseases of the Esophagus 2017;30:1-9. [DOI: 10.1093/dote/dox092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
555 Sugimura K, Miyata H, Matsunaga T, Asukai K, Yanagimoto Y, Takahashi Y, Tomokuni A, Yamamoto K, Hirofumi A, Nishimura J, Motoori M, Wada H, Takahashi H, Yasui M, Omori T, Ohue M, Yano M. Comparison of the modified Collard and hand-sewn anastomosis for cervical esophagogastric anastomosis after esophagectomy in esophageal cancer patients: A propensity score-matched analysis. Ann Gastroenterol Surg 2019;3:104-13. [PMID: 30697615 DOI: 10.1002/ags3.12220] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
556 Kijima T, Arigami T, Uchikado Y, Uenosono Y, Kita Y, Owaki T, Mori S, Kurahara H, Kijima Y, Okumura H, Maemura K, Ishigami S, Natsugoe S. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. Cancer Sci 2017;108:193-9. [PMID: 27889946 DOI: 10.1111/cas.13127] [Cited by in Crossref: 36] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
557 Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Suda K, Wada N, Kitagawa Y. Prognostic Impact of Change in the Fibrinogen and Albumin Score During Preoperative Treatment in Esophageal Cancer Patients. World J Surg 2017;41:2788-95. [PMID: 28608015 DOI: 10.1007/s00268-017-4074-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
558 Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Chiwaki F, Tamaoki M, Nishimura T, Takahashi N, Oda I, Tachimori Y, Arao T, Nishio K, Kitano S, Narumi K, Aoki K, Fujii S, Ochiai A, Yoshida T, Muto M, Yamada Y, Sasaki H. Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. PLoS One 2015;10:e0143804. [PMID: 26625258 DOI: 10.1371/journal.pone.0143804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
559 Fujiwara Y, Fukuda S, Tsujie M, Kitani K, Yukawa M, Inoue M, Watanabe Y, Higashida M, Kubota H, Okada T, Tsuruta A, Ueno T. Clinical significance of preoperative chemoradiotherapy for advanced esophageal cancer, evaluated by propensity score matching and weighting of inverse probability of treatment. Mol Clin Oncol 2019;10:575-82. [PMID: 31086666 DOI: 10.3892/mco.2019.1843] [Reference Citation Analysis]
560 Kaburagi T, Takeuchi H, Kawakubo H, Omori T, Ozawa S, Kitagawa Y. Clinical utility of a novel hybrid position combining the left lateral decubitus and prone positions during thoracoscopic esophagectomy. World J Surg 2014;38:410-8. [PMID: 24101023 DOI: 10.1007/s00268-013-2258-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
561 Atay SM, Blum M, Sepesi B. Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient? J Thorac Dis 2017;9:3626-9. [PMID: 29268359 DOI: 10.21037/jtd.2017.09.68] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
562 Del Calvo H, Nguyen DT, Chan EY, Chihara R, Graviss EA, Kim MP. Surgery provides improved overall survival in surgically fit octogenarians with esophageal cancer after chemoradiation therapy. J Thorac Dis 2021;13:5875-86. [PMID: 34795936 DOI: 10.21037/jtd-21-928] [Reference Citation Analysis]
563 Kojima H, Okumura T, Yamaguchi T, Miwa T, Shimada Y, Nagata T. Enhanced cancer stem cell properties of a mitotically quiescent subpopulation of p75NTR-positive cells in esophageal squamous cell carcinoma. Int J Oncol 2017;51:49-62. [PMID: 28534989 DOI: 10.3892/ijo.2017.4001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
564 Zhao Y, Dai Z, Min W, Sui X, Kang H, Zhang Y, Ren H, Wang XJ. Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial. J Thorac Oncol 2015;10:1349-56. [PMID: 26287319 DOI: 10.1097/JTO.0000000000000612] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
565 Komine O, Tanaka Y, Kawashima Y, Sakamoto H, Watanabe M, Suzuki H, Tokunaga A, Uchida E. Short-term postoperative superiority and 5-year follow-up outcomes of video-assisted thoracoscopic esophagectomy for treatment of esophageal carcinoma: a historical comparison with conventional open esophagectomy under a single experienced surgeon. Esophagus 2014;11:54-63. [DOI: 10.1007/s10388-013-0388-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
566 Ninomiya I, Okamoto K, Fujimura T, Fushida S, Osugi H, Ohta T. Oncologic Outcomes of Thoracoscopic Esophagectomy with Extended Lymph Node Dissection: 10-year Experience from a Single Center. World J Surg 2014;38:120-30. [DOI: 10.1007/s00268-013-2238-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
567 Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, Wang M, Min L, Liu X, Zhang X, Gubat JA, Chen Y. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther 2019;13:539-53. [PMID: 30787595 DOI: 10.2147/DDDT.S189514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
568 Ren Y, Ye J, Xiong W, Zuo J, He Y, Tan M, Yuan Y. Adjuvant radiotherapy for positive lymph nodes of oesophageal squamous cell carcinoma: Can it earn promising benefits at long-term follow-up? Cancer Radiother 2018;22:140-7. [PMID: 29454737 DOI: 10.1016/j.canrad.2017.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
569 Watkins AA, Zerillo JA, Kent MS. Trimodality Approach for Esophageal Malignancies. Surg Clin North Am 2021;101:453-65. [PMID: 34048765 DOI: 10.1016/j.suc.2021.03.007] [Reference Citation Analysis]
570 Tanaka Y, Yoshida K, Yamada A, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K, Miyazaki T. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2016;77:1143-52. [PMID: 26896963 DOI: 10.1007/s00280-016-2985-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
571 Sonoda A, Yoshida N, Shiraishi S, Horinouchi T, Tokunaga R, Harada K, Iwatsuki M, Nagai Y, Baba Y, Iwagami S, Miyamoto Y, Baba H. Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus. Ann Surg Oncol 2021;28:167-74. [PMID: 32588261 DOI: 10.1245/s10434-020-08738-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
572 Uchi Y, Takeuchi H, Matsuda S, Saikawa Y, Kawakubo H, Wada N, Takahashi T, Nakamura R, Fukuda K, Omori T, Kitagawa Y. CXCL12 expression promotes esophageal squamous cell carcinoma proliferation and worsens the prognosis. BMC Cancer 2016;16:514. [PMID: 27439769 DOI: 10.1186/s12885-016-2555-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
573 Murakami Y, Kawahara D, Tani S, Kubo K, Katsuta T, Imano N, Takeuchi Y, Nishibuchi I, Saito A, Nagata Y. Predicting the Local Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant Chemoradiotherapy by Radiomics with a Machine Learning Method Using 18F-FDG PET Images. Diagnostics (Basel) 2021;11:1049. [PMID: 34200332 DOI: 10.3390/diagnostics11061049] [Reference Citation Analysis]
574 Kitagawa H, Namikawa T, Iwabu J, Fujisawa K, Kobayashi M, Hanazaki K. Comparison between neck-first approach and thoracic approach during thoracoscopic esophagectomy. Langenbecks Arch Surg 2017;402:1159-65. [PMID: 29116434 DOI: 10.1007/s00423-017-1637-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
575 Tanaka Y, Ueno T, Yoshida N, Akutsu Y, Takeuchi H, Baba H, Matsubara H, Kitagawa Y, Yoshida K. The effect of an elemental diet on oral mucositis of esophageal cancer patients treated with DCF chemotherapy: a multi-center prospective feasibility study (EPOC study). Esophagus 2018;15:239-48. [PMID: 30225745 DOI: 10.1007/s10388-018-0620-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
576 Sohda M, Saito H, Kuriyama K, Yoshida T, Kumakura Y, Honjyo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Sakai M, Miyazaki T, Fukuchi M, Kuwano H. Post-esophagectomy Adjuvant Chemotherapy Benefits Esophageal Cancer Patients. In Vivo 2019;33:501-6. [PMID: 30804133 DOI: 10.21873/invivo.11502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
577 Fujiwara Y, Lee S, Kishida S, Hashiba R, Gyobu K, Naka R, Nishiyama M, Ihara T, Takemura M, Osugi H. Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma. Int J Clin Oncol 2018;23:877-85. [DOI: 10.1007/s10147-018-1291-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
578 Oguma J, Ozawa S, Koyanagi K, Kazuno A, Yamamoto M, Ninomiya Y, Yatabe K. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. Esophagus 2019;16:395-401. [DOI: 10.1007/s10388-019-00679-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
579 Nakatani M, Migita K, Matsumoto S, Wakatsuki K, Ito M, Nakade H, Kunishige T, Kitano M, Sho M. Prognostic Significance of the Prognostic Nutritional Index in Patients with Recurrent Esophageal Squamous Cell Carcinoma. Nutrition and Cancer 2018;70:467-73. [DOI: 10.1080/01635581.2018.1445771] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
580 Hayashi M, Abe M, Fujita T, Matsushita H. Assessing the Prognostic Value of Extranodal Extension in Esophageal Cancer from the Pathological Staging Perspective. J Invest Surg 2021;:1-9. [PMID: 34096439 DOI: 10.1080/08941939.2021.1912221] [Reference Citation Analysis]
581 Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, Tamura S, Kimura Y, Miyata H, Motoori M, Shiraishi O, Makino T, Satoh T, Mori M, Doki Y. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28:116-120. [PMID: 27687307 DOI: 10.1093/annonc/mdw439] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
582 Ohkura Y, Shindoh J, Ueno M, Iizuka T, Udagawa H. Clinicopathologic Characteristics of Oligometastases from Esophageal Cancer and Long-Term Outcomes of Resection. Ann Surg Oncol 2020;27:651-9. [PMID: 31898096 DOI: 10.1245/s10434-019-08175-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
583 Shiozaki A, Marunaka Y, Otsuji E. Roles of Ion and Water Channels in the Cell Death and Survival of Upper Gastrointestinal Tract Cancers. Front Cell Dev Biol 2021;9:616933. [PMID: 33777930 DOI: 10.3389/fcell.2021.616933] [Reference Citation Analysis]
584 Komatsu S, Ichikawa D, Kawaguchi T, Takeshita H, Miyamae M, Ohashi T, Okajima W, Imamura T, Kiuchi J, Arita T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Otsuji E. Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget. 2016;7:62034-62048. [PMID: 27566562 DOI: 10.18632/oncotarget.11500] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
585 Kubo N, Ohira M, Tamura T, Sakurai K, Toyokawa T, Tanaka H, Yashiro M, Yamashita Y, Hirakawa K. Prognostic significance of baseline nutritional index for patients with esophageal squamous cell carcinoma after radical esophagectomy. Esophagus 2017;14:84-90. [DOI: 10.1007/s10388-016-0548-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
586 Tanaka Y, Yoshida K, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Sci 2016;107:764-72. [PMID: 27061001 DOI: 10.1111/cas.12943] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
587 Sasaki K, Omoto I, Uchikado Y, Okumura H, Noda M, Tsuruda Y, Kita Y, Arigami T, Mori S, Kurahara H, Nakajyo A, Koriyama C, Natsugoe S, Ohtsuka T. Comparison of greater curvature and lesser curvature circular-stapled esophagogastrostomy after esophagectomy in patients with esophageal cancer: a prospective randomized controlled trial. Surg Today 2021;51:575-81. [PMID: 32974752 DOI: 10.1007/s00595-020-02147-8] [Reference Citation Analysis]
588 Soeno T, Harada H, Hosoda K, Mieno H, Ema A, Ushiku H, Washio M, Kosaka Y, Watanabe M, Yamashita K. Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy. Ann Surg Oncol 2019;26:996-1004. [DOI: 10.1245/s10434-019-07190-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
589 Okamura A, Watanabe M, Mine S, Kurogochi T, Yamashita K, Hayami M, Imamura Y, Ogura M, Ichimura T, Takahari D, Chin K. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma. Dis Esophagus 2017;30:1-8. [PMID: 28859367 DOI: 10.1093/dote/dox075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
590 Akiyama Y, Sasaki A, Endo F, Nikai H, Amano S, Umemura A, Baba S, Chiba T, Kimura T, Takahara T, Nitta H, Otsuka K, Mizuno M, Kimura Y, Koeda K, Iwaya T. Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. World J Surg Oncol 2018;16:122. [PMID: 29966526 DOI: 10.1186/s12957-018-1420-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
591 Goto M, Yoshida T, Yamamoto Y, Furukita Y, Inoue S, Fujiwara S, Kawakita N, Nishino T, Minato T, Yuasa Y, Yamai H, Takechi H, Seike J, Bando Y, Tangoku A. CXCR4 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2017;24:832-40. [PMID: 26577115 DOI: 10.1245/s10434-015-4974-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
592 Katada N, Yamashita K, Katada C, Moriya H, Hosoda K, Mieno H, Higuchi K, Komori S, Ishiyama H, Hayakawa K, Sugawara M, Tanabe S, Koizumi W, Kikuchi S, Watanabe M. Neoadjuvant chemotherapy using concurrent Docetaxel/CDDP/5-FU (DCF) in esophageal squamous cell carcinoma and its short-term prognosis. Esophagus 2014;11:173-81. [DOI: 10.1007/s10388-014-0422-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
593 Nishino T, Yoshida T, Inoue S, Fujiwara S, Goto M, Minato T, Furukita Y, Yamamoto Y, Yuasa Y, Yamai H, Takechi H, Toba H, Takizawa H, Yoshida M, Seike J, Miyoshi T, Tangoku A. Gender differences in clinicopathological features and prognosis of squamous cell carcinoma of the esophagus. Esophagus 2017;14:122-30. [DOI: 10.1007/s10388-016-0554-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
594 Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer Chemother Pharmacol 2015;76:357-63. [PMID: 26092324 DOI: 10.1007/s00280-015-2806-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
595 Saif MW, Vethody C. Poorly Differentiated Neuroendocrine Tumor of the Esophagus with Hypertrophic Osteoarthropathy and Brain Metastasis: A Success Story. Cureus 2016;8:e646. [PMID: 27446766 DOI: 10.7759/cureus.646] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
596 Peng J, Wang W, Dong T, Cai J, Ni P, Chen L. Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations. The Annals of Thoracic Surgery 2016;101:280-6. [DOI: 10.1016/j.athoracsur.2015.06.081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
597 Shiozaki A, Hikami S, Ichikawa D, Kosuga T, Shimizu H, Kudou M, Yamazato Y, Kobayashi T, Shoda K, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Konishi E, Marunaka Y, Otsuji E. Anion exchanger 2 suppresses cellular movement and has prognostic significance in esophageal squamous cell carcinoma. Oncotarget 2018;9:25993-6006. [PMID: 29899837 DOI: 10.18632/oncotarget.25417] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
598 Kataoka K, Nakamura K, Mizusawa J, Fukuda H, Igaki H, Ozawa S, Hayashi K, Kato K, Kitagawa Y, Ando N. Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. Br J Surg 2015;102:1088-96. [PMID: 26095389 DOI: 10.1002/bjs.9839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
599 Kanda M, Shimizu D, Miyata K, Maeda O, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Ando M, Kuwatsuka Y, Murotani K, Nakayama G, Koike M, Ando Y, Ebata T, Kodera Y. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial. Contemp Clin Trials Commun 2021;24:100853. [PMID: 34820548 DOI: 10.1016/j.conctc.2021.100853] [Reference Citation Analysis]
600 Ochi M, Murakami Y, Nishibuchi I, Kubo K, Imano N, Takeuchi Y, Kimura T, Hamai Y, Emi M, Okada M, Nagata Y. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma. J Radiat Res 2021;62:142-8. [PMID: 33392619 DOI: 10.1093/jrr/rraa110] [Reference Citation Analysis]
601 Forde PM, Kelly RJ. Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. J Thorac Oncol. 2013;8:673-684. [PMID: 23591158 DOI: 10.1097/jto.0b013e31828b5172] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
602 Yokota T, Igaki H, Kato K, Tsubosa Y, Mizusawa J, Katayama H, Nakamura K, Fukuda H, Kitagawa Y. Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial. Int J Clin Oncol 2016;21:283-8. [PMID: 26335243 DOI: 10.1007/s10147-015-0899-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
603 Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2018;155:2710-2721.e3. [PMID: 29548582 DOI: 10.1016/j.jtcvs.2018.01.086] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
604 Kumagai Y, Ishiguro T, Kuwabara K, Sobajima J, Fukuchi M, Ishibashi K, Baba H, Mochiki E, Aida J, Takemoto A, Kawano T, Takubo K, Ishida H. Primary mucoepidermoid carcinoma of the esophagus: review of the literature. Esophagus 2014;11:81-8. [DOI: 10.1007/s10388-014-0414-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
605 Monma S, Kato K, Shouji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N, Nagashima K, Ito Y, Itami J. Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer. Esophagus 2019;16:402-7. [PMID: 31222680 DOI: 10.1007/s10388-019-00680-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
606 Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg 2013;61:330-5. [PMID: 23568356 DOI: 10.1007/s11748-013-0246-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 8.7] [Reference Citation Analysis]
607 Matsuda S, Tsubosa Y, Niihara M, Sato H, Takebayashi K, Kawamorita K, Mori K, Tsushima T, Yokota T, Ogawa H, Onozawa Y, Yasui H, Takeuchi H, Kitagawa Y. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. Ann Surg Oncol 2015;22:1866-73. [PMID: 25564176 DOI: 10.1245/s10434-014-4337-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
608 Yamawaki C, Takahashi M, Takara K, Kume M, Hirai M, Yasui H, Nakamura T. Effect of dexamethasone on extracellular secretion of cystatin C in cancer cell lines. Biomed Rep 2013;1:115-8. [PMID: 24648905 DOI: 10.3892/br.2012.21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
609 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25-43. [PMID: 30171414 DOI: 10.1007/s10388-018-0642-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 29.3] [Reference Citation Analysis]
610 Akiyama Y, Iwaya T, Endo F, Nikai H, Sato K, Baba S, Chiba T, Kimura T, Takahara T, Otsuka K, Nitta H, Mizuno M, Kimura Y, Koeda K, Sasaki A. Thoracoscopic esophagectomy with total meso-esophageal excision reduces regional lymph node recurrence. Langenbecks Arch Surg 2018;403:967-75. [PMID: 30413880 DOI: 10.1007/s00423-018-1727-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
611 Yoshida N, Baba Y, Watanabe M, Ida S, Ishimoto T, Karashima R, Iwagami S, Imamura Y, Sakamoto Y, Miyamoto Y, Baba H. Original scoring system for predicting postoperative morbidity after esophagectomy for esophageal cancer. Surg Today. 2015;45:346-354. [PMID: 24997754 DOI: 10.1007/s00595-014-0958-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
612 Shiraishi O, Yasuda T, Kato H, Momose K, Hiraki Y, Yasuda A, Shinkai M, Kimura Y, Imano M. Comparison of Aggressive Planned Salvage Surgery Versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma. Ann Surg Oncol 2021. [PMID: 33768398 DOI: 10.1245/s10434-021-09875-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Ishibashi Y, Tsujimoto H, Einama T, Mochizuki S, Kouzu K, Nomura S, Ito N, Harada M, Sugasawa H, Shinto E, Kishi Y, Ueno H. Correlation Between Immunoinflammatory Measures and Periostin Expression in Esophageal Squamous Cell Carcinoma: A Single-Center, Retrospective Cohort Study. Ann Surg Oncol 2021;28:1228-37. [PMID: 32613365 DOI: 10.1245/s10434-020-08765-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
614 Booka E, Takeuchi H, Nishi T, Matsuda S, Kaburagi T, Fukuda K, Nakamura R, Takahashi T, Wada N, Kawakubo H, Omori T, Kitagawa Y. The Impact of Postoperative Complications on Survivals After Esophagectomy for Esophageal Cancer. Medicine (Baltimore) 2015;94:e1369. [PMID: 26287423 DOI: 10.1097/MD.0000000000001369] [Cited by in Crossref: 93] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
615 Ishikura S, Kondo T, Murai T, Ozawa Y, Yanagi T, Sugie C, Miyakawa A, Shibamoto Y. Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease. J Radiat Res 2020;61:464-9. [PMID: 32249307 DOI: 10.1093/jrr/rraa008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
616 Nakajima M, Kato H. Treatment options for esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy 2013;14:1345-54. [DOI: 10.1517/14656566.2013.801454] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
617 Sato H, Saito T, Horii H, Kajiura M, Kikuchi N, Takada N, Taguchi K, Yoshida M, Hasegawa M, Taguchi H, Yoshida Y, Ando K, Fujiya M, Omori Y, Hank T, Liss AS, Gala MK, Makita Y, Ono Y, Mizukami Y, Okumura T. Case Report: A Rare Case of Esophagogastric Junctional Squamous Cell Carcinoma After the Successful Treatment of Neuroendocrine Carcinoma: Clonal Tumor Evolution Revealed by Genetic Analysis. Front Genet 2021;12:608324. [PMID: 34616420 DOI: 10.3389/fgene.2021.608324] [Reference Citation Analysis]
618 Hara T, Makino T, Yamasaki M, Tanaka K, Yamashita K, Nogi Y, Saito T, Takahashi T, Kurokawa Y, Tatsumi M, Nakajima K, Morii E, Eguchi H, Doki Y. Peritumoral Lymphatic Vessels Associated with Resistance to Neoadjuvant Chemotherapy and Unfavorable Survival in Esophageal Cancer. Ann Surg Oncol 2020;27:3762-9. [PMID: 32328984 DOI: 10.1245/s10434-020-08474-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
619 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma. J Thorac Dis 2017;9:200-4. [PMID: 28203424 DOI: 10.21037/jtd.2017.01.44] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
620 Nakayama T, Furuya S, Kawaguchi Y, Shoda K, Akaike H, Hosomura N, Amemiya H, Kawaida H, Sudoh M, Kono H, Ichikawa D. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy. Nutrition 2021;90:111232. [PMID: 33964490 DOI: 10.1016/j.nut.2021.111232] [Reference Citation Analysis]
621 Tang H, Tan L, Wang H, Shen Y, Yin J. Nodal Downstaging of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy: Survival Analysis if ypN0 Is Achieved. J Gastrointest Surg 2020;24:1469-76. [DOI: 10.1007/s11605-019-04317-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
622 Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Kitagawa Y. Correlation Between Intense Postoperative Inflammatory Response and Survival of Esophageal Cancer Patients Who Underwent Transthoracic Esophagectomy. Ann Surg Oncol 2015;22:4453-60. [PMID: 25893412 DOI: 10.1245/s10434-015-4557-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
623 Kano K, Aoyama T, Nakajima T, Maezawa Y, Hayashi T, Yamada T, Sato T, Oshima T, Rino Y, Masuda M, Cho H, Yoshikawa T, Ogata T. Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis. BMC Cancer 2017;17:812. [PMID: 29202716 DOI: 10.1186/s12885-017-3831-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
624 Ishikawa T, Yasuda T, Okayama T, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Shiozaki A, Fujiwara H, Konishi H, Naito Y, Teramukai S, Itoh Y. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Cancer Sci 2019;110:3754-60. [PMID: 31646714 DOI: 10.1111/cas.14218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
625 Kitagawa H, Namikawa T, Munekage M, Fujisawa K, Kawanishi Y, Kobayashi M, Hanazaki K. Preoperative patient-related factors associated with prognosis after esophagectomy for esophageal cancer. Esophagus 2017;14:360-5. [DOI: 10.1007/s10388-017-0586-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
626 Wang Z, Mao Y, Gao S, Li Y, Tan L, Daiko H, Liu S, Chen C, Koyanagi K, He J. Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy. Ann N Y Acad Sci 2020;1481:20-9. [PMID: 32671860 DOI: 10.1111/nyas.14427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
627 Wong IYH, Lam KO, Chan W, Wong C, So TH, Chan KK, Choi CW, Law TT, Chiu K, Chan FSY, Kwong DLW, Law S. Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma. J Gastrointest Surg 2020;24:1937-47. [DOI: 10.1007/s11605-020-04704-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
628 Zheng Y, Liu X, Zhang R, Wang Z, Sun H, Qin J, Liu S, Li Y. Neoadjuvant chemotherapy with or without neoadjuvant radiotherapy compared with neoadjuvant chemoradiotherapy for esophageal cancer. J Thorac Dis 2018;10:4715-23. [PMID: 30233843 DOI: 10.21037/jtd.2018.07.124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]